

November 11, 2010.

CURRICULUM VITAE

Edward Denis JANUS
 Date of Birth: 6/11/44
 Married - 2 children.

Qualifications:

| | |
|---|--------------|
| M.B. Ch.B. (Otago) | 05/12/68 |
| M.R.A.C.P. | 08/03/73 |
| F.R.A.C.P. | 21/05/76 |
| M.D.(Otago) with Distinction | 16/12/76 |
| Ph.D. (London) in Faculty of Medicine | 25/01/78 |
| F.R.C.P.A. | 21/11/85 |
| F.A.C.B. (National Academy of Clinical Biochemists, U.S.A.) | January 1987 |
| F.C.C.P. (American College of Chest Physicians) | 20/01/93 |
| F.H.K.A.M. (Medicine & Pathology) | 1993 |
| FCSANZ (Cardiac Society of Australia & New Zealand) | 2006 |

Honours/Prizes:

| | |
|--|------|
| University National Scholar - New Zealand | 1962 |
| Smith Biolab Award (New Zealand Society of Pathologists/RCPA) | 1974 |
| International Society for Heart Research | 1986 |
| AACB Pacific Diagnostic Award | 1991 |
| Excellent Research Award, Food and Health Bureau, Government Secretariat of the Hong Kong SAR, Peoples Republic of China | 2007 |

Specialist Registration:

| | |
|--|---------|
| In General Medicine (The Medical Council of New Zealand) | 30/6/78 |
| Specialist Physician(General Medicine)-Victoria | 20/5/85 |
| Consultant Physician (in Endocrinology) and Specialist in Pathology - Victoria | 11/8/86 |

Theses:

- M.D. Alpha-1-antitrypsin deficiency: A study of the genetic variants of human alpha-1-antitrypsin found in New Zealand and their clinical implications.
- Ph.D. Plasma lipoprotein metabolism in man: Studies of apolipoprotein-B kinetics in the hyperlipidaemic states.

Appointments:

| | | | |
|---------|---|---|------------------|
| 1969/70 | Houseman |) | North Canterbury |
| 1971 | Registrar in Clinical Biochemistry |) | Hospital Board, |
| 1972/73 | Medical Registrar |) | Christchurch, |
| 1973/74 | Senior Registrar in Clinical Biochemistry |) | New Zealand |

- 1975 Registrar in Medicine and Chemical Pathology,
Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
- 1976/7 Senior Registrar, Department of Chemical Pathology and Metabolic Diseases,
St.Thomas's Hospital, London, UK.
- 1977 Senior Registrar, Professorial Medicine Unit,
King's College Hospital, London, UK.
- 1978 Senior Medical Registrar,
North Canterbury Hospital Board, Christchurch, New Zealand.
- 1978/84 Physician in Lipid Disorders, General Medicine and Chemical Pathology, The
Princess Margaret Hospital, Christchurch, New Zealand.
- 1979/84 Clinical Lecturer, Department of Medicine,
The Christchurch Clinical School of Medicine,
University of Otago, Christchurch, New Zealand.
- 1979/84 Consultant to Pearson Private Pathology Laboratory,
Christchurch, New Zealand.
- 1984-92 Director of Chemical Pathology, St.Vincent's Hospital, Melbourne, Australia.
- 1985-92 Senior Associate in the Dept. of Medicine,
University of Melbourne.
- 1985-86 Physician, Lipid Clinic, St.Vincent's Hospital.
- 1985-90 Assistant Physician, Respiratory Clinic, St.Vincent's Hospital.
- 1987-92 Physician in charge, Lipid Clinic, St.Vincent's Hospital.
- 1989-92 Physician, Epworth Cardiovascular Unit, Epworth Hospital, Melbourne.
- 1990-92 Physician, Respiratory Clinic, St.Vincent's Hospital.
- 1991 Acting Honorary Endocrinologist to the Austin Hospital for the period 1st July, 1991
to 31st December, 1991. (Sabbatical leave attachment).
- 1991-92 Visiting Associate - Diabetes and Endocrinology,
The Royal Melbourne Hospital, (Sabbatical leave attachment).
- 1991-92 Consultant Physician - Footscray Clinic, Melbourne.
- 1992- Consultant in Chemical Pathology, St. Vincent's Hospital,
Melbourne, Australia (Appointed 24/11/92).
- 1992-97 Senior Consultant, Clinical Biochemistry Unit (Queen Mary Hospital), University of
Hong Kong.
- 1992-97 Honorary Clinical Professor in Clinical Biochemistry,
University of Hong Kong.

- 1992-97 Honorary Clinical Associate, Department of Medicine, University of Hong Kong.
- 1994-97 Chief of Service, Department of Clinical Biochemistry, Queen Mary Hospital.
- 1997-99 Director of Biochemistry, Royal Women's and Children's Health Care Network, Melbourne, Australia (from 17.6.1997).
- 1997-99 Professorial Associate (with title of Professor) in the Department of Paediatrics, The University of Melbourne, Australia (from 17.6.1997).
- 1997-99 Director, Division of Laboratory Services, Women's and Children's Health Care Network, Melbourne, Australia (from 4.9.1997).
- 1998- Honorary Senior Fellow, The Murdoch Institute for Research into Birth Defects.
- 1999-00 Consultant Physician, Warrnambool Physicians Group, Warrnambool, Vic, Australia.
- 1999-00 Accredited physician, Warrnambool Base Hospital and St John of God Hospital, Warrnambool, Victoria, Australia.
- 2000-06 Physician, Director of Medicine and Intensive Care, Wimmera Health Services, Wimmera Base Hospital, Horsham, Victoria, Australia
- 2000-05 Principal Fellow/Associate Professor, Dept of Medicine, The Royal Melbourne and Western Hospital Clinical School, University of Melbourne, Melbourne, Australia.
- 2004-05 Professor/Senior Clinical Consultant in Greater Green Triangle University Department of Rural Health, School of Medicine, Faculty of Health Sciences, Flinders University, Adelaide, Australia.
- 2006- Adjunct Professor in Greater Green Triangle University Department of Rural Health, School of Medicine, Faculty of Health Sciences, Flinders University, Adelaide, Australia - extended to 30/6/13 in July 2010.
- 2006- Head of General Internal Medicine Unit, Western Health, Footscray, Victoria, Australia
- 2006- Professorial Fellow, Department of Medicine, Western Hospital, University of Melbourne, Melbourne, Australia

Professional and Other Positions Held

In New Zealand (1978 - 1984)

- (i) Chairman, Human Genetics Society of Australasia, New Zealand Branch, 1984.
- (ii) Secretary, Christchurch Hospitals Medical Staff Association, 1983/4.
- (iii) Convenor, Continuing Education Programme for Christchurch Physicians, 1983.
- (iv) M.Sc. Examiner for University of Otago (1983) for thesis "The alpha-1-antitrypsin isoforms in health and stress".
- (v) M.Appl.Sc. Supervisor (Lincoln College, University of Canterbury) 1983/5 for thesis - "Genetic variants of Apolipoproteins". Awarded 1985 - 1st class Honours. NZACB Abbott Award 1986.
- (vi) Member of Canterbury Medical Research Foundation Medical Advisory Committee 1982/4.
- (vii) Member Research Ethical Committee, North Canterbury Hospital Board, 1982/4.
- (viii) Ph.D. Supervisor, University of Otago, 1981 - 1984 for thesis "The characterisation of the variants of human apolipoprotein E associated with dyslipoproteinaemias". (Awarded 1986).
- (ix) Chairman, Christchurch Medical Research Society 1980/1.
Secretary, Christchurch Medical Research Society 1978/80.
- (x) Chairman, Canterbury Branch, New Zealand Association of Clinical Biochemists, 1979/82.
- (xi) Organiser - Part 1 F.R.A.C.P. Clinical Examinations for New Zealand 1979 and 1980.
- (xii) Supervisor for final year B.Agr.Sci.
Project - "VLDL apoprotein variants" in 1980.
Degree awarded with 1st Class Honours.
- (xiii) Ph.D. Examiner for University of Otago (1978) for thesis - "Very low density lipoproteins in rabbits fed cholesterol".

In Australia/Overseas (1985 on)

- (i) Chairman. Australian Association of Clinical Biochemists (A.A.C.B.) (Victorian Branch) 1985/86/87.
- (ii) M.Sc. Examiner for University of Melbourne (1985) for thesis - "The isolation and characterization of human apolipoprotein cDNA clones".
- (iii) Member Human Genetics Society of Australasia (H.G.S.A.) Victorian Branch Committee 1985/6.
- (iv) Chairman, Diet and Heart Disease Subcommittee, Victorian Division, National Heart Foundation of Australia. 1985 - 1992.
- (v) Member - Medical Advisory Committee - National Heart Foundation of Australia (Victorian Division). 1985 - 1992.

- (vi) Deputy Chairman. Division of Clinical Sciences. St.Vincent's Hospital Senior Medical Staff, 1986 - 88.
- (vii) Member. Council of the Senior Medical Staff. St.Vincent's Hospital, 1986 - 88.
- (viii) Chairman, Pathology Services Subcommittee. St.Vincent's Hospital, 1986 - 88.
- (ix) Treasurer, Australian Atherosclerosis Society, 1986 - 88.
- (x) Member Victorian State Committee. Royal Australasian College of Pathologists, 1987 - 1989.
- (xi) Member National Heart Foundation of Australia, National Diet and Heart Disease Advisory Committee, 1987 - 1992.
- (xii) NATA assessor for Chemical Pathology Laboratories, 1987 - 1992.
- (xiii) Member. St.Vincent's Institute of Medical Research 1988 - .
- (xiv) Member. Editorial Board, Advances in Clinical Chemistry 1988 - .
- (xv) Member. New York Academy of Sciences. 1988 - .
- (xvi) Member Cardiovascular Drugs Sub Committee of Victorian Drug Usage Advisory Committee 1989 - 1990.
- (xvii) Chairman Health Service Agreement Working Party, St.Vincent's Hospital, 1989.
- (xviii) Reviewer, Journal of Lipid Research (USA), 1989 - .
- (xix) Grant reviewer:
 - (a) MRC (NZ) - from 1986
 - (b) Health Research Council of NZ - from 1991
 - (c) NH & MRC (Australia) - from 1987
 - (d) National Heart Foundation of New Zealand from 1985
 - (e) National Heart Foundation of Australia from 1987. Member Research Grants interview committee 1990 & 1991.
 - (f) Commonwealth Department of Veteran Affairs - 1992.
 - (g) Ramaciotti Foundation 1992.
 - (h) Western Australian Health Promotion Foundation from 1992.
- (xx) M.D. Co-Supervisor, University of Melbourne, Dr A.Jenkins "Hyperlipidaemia in Diabetes Mellitus", 1989 - 91. MSD Fellow - Sandoz Prize. MD Awarded February, 1993.
- (xxi) M.Sc. Examiner, University of Melbourne (1989) for thesis "Regulation of plasma lipoprotein levels and composition".
- (xxii) Visiting assignment, Hospital Universiti Sains Malaysia, Kota Bharu - International Development Program of Australian Universities and Colleges. March, 1990.
- (xxiii) Ph.D. Examiner, University of Western Australia (1990) for thesis

"An insight into high density lipoprotein phospholipid metabolism in control and insulin-deficient rats".

- (xxiv) M.D. Examiner, University of Adelaide (1992) for thesis "Molecular analyses of alpha-1-antitrypsin variation and deficiency".
- (xxv) Member. Cardiac Society of Australia and New Zealand 1992 - .
(Associate member 1983-92)

In Hong Kong/Overseas (1992 - 1997)

- (i) Fellow. Hong Kong College of Pathologists 1992 - .
- (ii) Examiner in Chemical Pathology. Hong Kong College of Pathologists, 1992 -94; Chief Examiner 1994 - 1997.
- (iii) Examiner in Clinical Biochemistry. Hong Kong Medical Laboratory Technologists Board 1993 - 1997.
- (iv) Chairman, Scientific Committee.
Hong Kong Society of Clinical Chemists, 1993 - 1997.
- (v) Member, Board of Accreditation.
Hong Kong Society of Clinical Chemists, 1993 - 1997.
- (vi) Fellow, Hong Kong College of Cardiologists, 1993 - .
- (vii) Ph.D. Examiner, Murdoch University, Western Australia, "Human phospholipase A2 and its relationship to the biochemistry of disease states".
- (viii) Ph.D. Supervisor, University of Hong Kong, Mr. R.W.C. Pang, "Genetic and environmental influences on the phenotypic expression of apolipoprotein(a) and their implications for atherogenesis", 1993-1997. Thesis submitted February, 1997. Awarded Faculty of Medicine Medical Research Week Prize - January 1997. Ph.D awarded December 1997.
- (ix) Ph.D. Supervisor, University of Hong Kong, Mr. Paul, W.C. Li, "Lp(a) in renal disease", 1993-1994 (withdrew May, 1994).
- (x) Ph.D. Examiner (additional), University of Hong Kong (1993), "Physical status of mitochondrial aspartate aminotransferase in serum and the role of α 2-macroglobulin in its clearance".
- (xi) Ph.D. Supervisor, (after departure of Prof. T. Boyde), University of Hong Kong (1993), Ms. Rukhsana Usman Simjee, "Platelet activity and arachadonic acid metabolism modulation by factors in plasma and cerebrospinal fluid and by diet". Ph.D. awarded - June, 1994.
- (xii) Ph.D. Examiner (additional), Chinese University of Hong Kong (1993), "Development of an immunoassay for bone-specific acid phosphatase and its use for studying bone metabolism".
- (xiii) Convenor, Hong Kong Heart Health Steering Committee, 1993 - 1997.
- (xiv) Fellow, Hong Kong College of Physicians, 1993 - .

- (xv) Foundation Fellow, Hong Kong Academy of Medicine in Medicine and Pathology, December, 1993.
- (xvi) Chairman, Queen Mary Hospital Staff Safety Committee, 1993 - 1997.
- (xvii) Chairman, Hong Kong College of Pathologists & HOKLAS Laboratory Accreditation Steering Committee, 1993 - .
- (xviii) Ph.D. Supervisor, University of Hong Kong, Mr. O.C.K. Ma. Genetic variation in Fibrinogen, 1994 only (withdrew).
- (xix) Member, International Society and Federation of Cardiology, Council on Arteriosclerosis, 1993 - .
- (xx) Member, International Scientific Advisory Committee, January, 1994, Asian-Pacific Congress on Lipid Risk Factor Control.
- (xxi) M.Sc. Examiner, Chinese University of Hong Kong, 1994 for thesis Chemiluminescence of radical trapping activity.
- (xxii) Consultant, Scientific Programme ASEANZ Lipid Forum, Taiwan, June 1994.
- (xxiii) Member, Council of the Hong Kong College of Pathologists, 1994 - 1996.
- (xxiv) Member, Training & Examination Committee, Hong Kong College of Pathologists, 1994 - 1997.
- (xxv) Chairman, Quality Assurance Committee, Hong Kong College of Pathologists, 1994 - 1997 .
- (xxvi) Member, Council of the Hong Kong Society of Clinical Chemists, 1994 - 1997.
- (xxvii) Member, Education Committee, Hong Kong Society of Clinical Chemists, 1994 - 1997.
- (xxviii) M.Phil. Examiner, University of Hong Kong (1994), "Bioavailability problems in clinical neuropharmacology with special reference to (1) Generic phenytoin and (2) Madopar HBS".
- (xxix) Member, Coordinating Committee in Pathology, Hospital Authority, Hong Kong, 1994 - 1997.
Chairman, Training Subcommittee, 1994 - 1997.
Member, Service Development Subcommittee, 1994 - 1997.
- (xxx) PhD Supervisor, University of Ulster at Coleraine, Londonderry, Northern Ireland (1994 - 1996).
Ms. Iris Benzie, "Dietary antioxidants, LDL oxidation and coronary heart disease, relationships and possible mechanisms of prevention of disease". Awarded July 1996.
- (xxxi) Secretary and Foundation Member, Asian Pacific Society of Atherosclerosis and Vascular Diseases, 1995 - .
- (xxxii) External Examiner, Master of Medicine (Pathology) Part I. Universiti Sains Malaysia, Kota Bharu, Malaysia, 1995.
- (xxxiii) Chairman of Scientific and Organizing Committee, ASEANZ Lipid Forum, Cebu, Philippines, May, 1995.
- (xxxiv) Examiner in Chemical Pathology, Royal Australasian College of Pathologists, 1995 - .

- (xxxv) M.Phil. Supervisor, University of Hong Kong, Mr. Simon Tak Shing Siu , "A sensitive method for measuring plasma catecholamines and its application on the study of the effect of alfentanil and esmolol on intra-operative hypertension". Awarded M. Phil. August 1998.
- (xxxvi) Ph.D. Examiner, University of Sydney (1995) for thesis "Factors affecting triglyceride - rich and high density lipoproteins".
- (xxxvii) Member, International Advisory Panel, Malaysian Journal of Medical Sciences, 1996.
- (xxxviii) Representative, Asian Pacific region, ISFC/WHO Task Force on risk factors for cardiovascular disease in developing countries, 1996 -
- (xxxix) Member of Scientific Committee, The 1st Congress of the Asian-Pacific Society of Atherosclerosis and Vascular Diseases, Taipei, March, 1998.
- (xxxx) Member (invited) of the International Advisory Board 4th International Symposium Multiple Risk Factors in Cardiovascular Disease, Washington, D.C. (USA), April, 1997.
- (xxxxi) Member, Editorial Board, Atherosclerosis, from August 1996 - June 2007.
- (xxxxii) M.Phil. Supervisor, University of Hong Kong, Ms. Ng S.W., "Hyperhomocysteinaemia and heart disease", December 1996 - March 1997 (withdrew).
- (xxxxiii) Ph.D. Co-supervisor, University of Hong Kong, Dr. L.J. Liu, "The relationship between fibrinogen and other risk factors for CHD in Hong Kong". Commenced June, 1994. Appointed co-supervisor January, 1997. Submitted PhD March 1998. Awarded October 1998.
- (xxxxiv) Ph.D. Supervisor, University of Sydney, Ms. Gemma Ritchie, "Patterns of care in coronary disease in the Asian Pacific Region". Commenced April, 1997.

In Australia / Overseas (1997 on)

- (i) Coopted Member, International Task Force for Prevention of Coronary Heart Disease, 1997 -
- (ii) Chairman, Scientific Committee, for 1999 AACB Annual Conference in Melbourne, Australia, 1997 -1999.
- (iii) M.Phil Examiner (External), 1998, Chinese University of Hong Kong, Poon Mei Yu's thesis "The distribution and volume of visceral and subcutaneous adipose tissue derived from spiral CT examination".
- (iv) Reviewer, The American Journal of Cardiology, 1998 -
- (v) Chairman elect, Asian Pacific Society of Atherosclerosis and Vascular Diseases, 1998 - 1999
Chairman 1999 to 2002, Treasurer 2002 – 2005, 2005 - 2008.
- (vi) Member Faculty Board, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, 1998-1999.

- (vii) PhD Examiner (External), 1998, University of Hong Kong, for Chaya Sudhir Ambebekar's Thesis "Metabolism of chloramphenicol by human bone marrow : A comparison of Chinese and Caucasian populations.
- (viii) Reviewer (1998), National University of Singapore for promotion to full professorship.
- (ix) Visiting Professor, Clinical Trials Centre, Faculty of Medicine, University of Hong Kong, October, 1998.
- (x) Member, International Editorial Board, Journal of the Indian College of Cardiology, 1999-
- (xi) Member (1999) of the International Advisory Board 5th International Symposium : Multiple Risk Factors and Cardiovascular Disease. Global Assessment and Intervention . Venice, Italy October 28 - 31, 1999.
- (xii) Member International Scientific Advisory Committee, 72nd European Atherosclerosis Society Congress, Glasgow 20 - 23 May, 2001, from 1999-2001.
- (xiii) Chairman Elect, World Heart Federation, Council on Arteriosclerosis, 1999. Chairman 1999- 2003.
- (xiv) Member, Scientific Advisory Board, World Heart Federation 1999 – 2003.
- (xv) Member, International Advisory Board, XIV International Symposium on Drugs Affecting Lipid Metabolism, New York, USA, September 9 – 13, 2001.
- (xvi) Member, Clinical Cardiology Committee, Asian Pacific Society of Cardiology 2000-
- (xvii) Member, Scientific Advisory Board 3rd Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases, Cebu, Philippines, February 17 –21, 2001.
- (xviii) Member, International Advisory Board, World Congress of Cardiology, Sydney, Australia, May 5 – 9, 2002.
- (xix) Reviewer RGC Hong Kong 2000-
- (xx) Member, International Advisory Board, 6th International Symposium on Global Risk of Coronary Heart Disease and Stroke: Assessment, Prevention and treatment, Florence, Italy, June 12 – 15, 2002
- (xxi) Chairman, Medical Staff Group, Wimmera Health Care Group, Horsham, VIC., 2001- 2003.
- (xxii) Chairman, Pharmacy Advisory Committee, Wimmera Health Care Group, 2002 – 2003
- (xxiii) Reviewer Heart, Lung and Circulation 2002-
- (xxiv) PhD examiner (2002), University of Western Australia for Chi-Fai Chan's thesis "Role of Lipid Substrate Availability in the Regulation of Lipoprotein Kinetics in Obese Men".
- (xxv) Member International Advisory Board IAS 2003 Satellite Symposium, September 24 – 27, 2003. Taipei, Taiwan.

- (xxvi) XIIIth International Symposium on Atherosclerosis, Kyoto, Japan, September 28 – October 2, 2003. Co-organizer and Guest Speaker for Workshop “ Hypertension, Diabetes Mellitus, Hyperlipidaemia and Obesity in Asia and the Pacific”.
- (xxvii) 5th Hong Kong Diabetes and Cardiovascular Risk Factors - East meets West Symposium and Satellite Meeting of 13th International Symposium on Atherosclerosis, Hong Kong, 3rd – 5th October, 2003. Member of International Faculty.
- (xxviii) PhD Examiner (2003), University of Western Australia for Richard Woodman’s thesis “The independent effects of purified EPA and DHA on cardiovascular risk in treated- hypertensive type 2 diabetic individuals.
- (xxix) University of Western Australia (2003), Assessor of applications for Adjunct and Clinical Associate Professor within the Faculty of medicine and dentistry.
- (xxx) NH & MRC (2003), Assessor of application for Senior Principal Research Fellow.
- (xxxi) Research Grants Council of Hong Kong (RGC) (2003 and 2004) Reviewer of (three) Research Grant Proposals in each year.
- (xxxii) Associate Editor, Journal of Atherosclerosis and Thrombosis (Japan) from 2003.
- (xxxiii) Member International Advisory Committee, 4th Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases, Bali, Indonesia. 6 – 9 May, 2004.
- (xxxiv) International advisor “A Course on Diabetes and Vascular Disease”, organised by Philippines Diabetes Association and Asian Pacific Society of Atherosclerosis and Vascular Diseases. Manila, Philippines, October 15 – 16, 2004.
- (xxxv) PhD Examiner University of Western Australia (2005) for thesis “Lipid kinetics in metabolic syndrome.”
- (xxxvi) Member International Advisory Committee, 5th Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases, Jeju, Korea, 12-15 April, 2006.
- (xxxvii) Reviewer NHMRC grants, 2007-
- (xxviii) Reviewer National Heart Foundation of Australia grants, 2007-
- (xxxix) Reviewer National Heart Foundation Career Development Fellowship and Post Doctoral Fellowship 2007.
- (xl) Reviewer Flinders University Level D (Associate Professor) promotion application, 2007.
- (xli). Reviewer Australian Journal of Rural Health, 2007 -
- (xlii). Member Department of Human Services Outpatient Experience Subcommittee, 2007-2009.
- (xliii). Reviewer for Diabetes UK grant application, 2007.
- (xliv). PhD Examiner University of Western Australia (2007) for thesis “Studies on Lipoprotein kinetics in obesity and the metabolic syndrome: Impact of dietary weight loss and statin therapy.

- (xlv). Reviewer for UK Sheffield Hospitals Charitable Trust research grant application 2008.
- (xlvi) Member International Advisory Committee, 6th Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases, Hong Kong, 25-28 September, 2008.
- (xlvii) Chairman Western Health Pathology Committee, 2007-
- (xlviii) Member Western Health Clinical Services Taskforce, 2008-
- (xlix) Member Western Health Outpatients Reference Group, 2007- 2009
- (l) Member Department of Health Parkville Pathology Reference Group, 2008- 2009
- (li) Member International Advisory Committee, 7th Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases, Cairns, 19-22 October, 2010.
- (lii) Member Department of Health Acute Medical Inpatients Advisory Committee, 2010-
- (liii) Member Organizing Committee, General Medicine Clinical Weekend - “Clinical Internal Medicine for Advanced Trainees and Consultants”, Torquay, Victoria, 15-16 October 2010.
- (liv).Member Executive Committee for the Regional Federation for Asia Pacific of the International Atherosclerosis Society, 2010-
- (lv).Western Health Model of Care Project 2010
 - Chairman Strategic Group
 - Member Methodology Development Group
 - Chairman “Unscheduled Care” Model of Care Group

Publications

1. Milk and Blood Alcohol.
E.D. Janus and J.R. Sharman (1972).
N.Z.Med.J. 75:339-342.
2. Hashimoto's Thyroiditis and Homozygous Alpha-1-antitrypsin Deficiency.
M.G. Nicholls and E.D. Janus (1973).
Aust. N.Z. J. Med. 3:516-519.
3. The Laboratory Diagnosis of Alpha-1-antitrypsin Deficiency.
P.R. Joyce and E.D. Janus (1974).
N.Z. J. Med. Lab. Technol. 28:72-77.
4. Drug Overdoses: Is one Stomach Washing Enough?
J.R. Sharman, M.J. Cretney, R.D. Scott and E.D. Janus (1975).
N.Z. Med. J. 81:195-197.
5. Alpha-1-antitrypsin Deficiency in New Zealand.
E.D. Janus and R.W. Carrell (1975).
N.Z. Med.J. 81:461-467.
6. Alpha-1-antitrypsin Variants in New Zealand.
E.D. Janus, P.R. Joyce, J.M. Sheat and R.W. Carrell (1975).
N.Z. Med.J. 82:289-293.
7. Alpha-1-antitrypsin Deficiency and Adult Liver Disease.
E.D. Janus and R.W. Carrell (1975).
Proceeding XXIIIrd. Colloquium "Protides of the Biological Fluids".
p 383-385.
8. The Evaluation of Lipoprotein Changes during Gemfibrozil Treatment.
E.D. Janus, D. Costa, I.C. Ononogbu and B. Lewis (1976).
Proc. R. Soc. Med. 69. Suppl. 2:76-77.
9. Very Low Density Lipoprotein Metabolism in Familial Hyperlipoproteinaemias.
E.D. Janus, A. Nicoll and B. Lewis (1977).
XXVth Colloquium "Protides of the Biological Fluids".
p 171-174.
10. Effects of Dietary Cholesterol on Serum Lipoproteins in Man.
P. Mistry, A. Nicoll, C. Niehaus, I. Chrystie, E.D. Janus, H. Strain and B. Lewis (1977).
XXVth Colloquium "Protides of the Biological Fluids".
p 349-352.
11. Quantitation of Very Low Density (VLDL) to Low Density Lipoprotein (LDL) in Normal and Hyperlipidaemic Man.
E.D. Janus, R. Wootton, A. Nicoll, P. Turner and B. Lewis (1977).
Circulation 56, Suppl. III:21.
12. Substrate Specificities of Human Hepatic Lipase and Lipoprotein Lipase.
A. Nicoll, E.D. Janus, G. Sigurdsson and B. Lewis (1977).
Circulation 56, Suppl. III:23.

13. Alcohol and Abnormalities of Lipid Metabolism.
E.D. Janus and B. Lewis (1978).
Clin. Endocrinol. Metab. 7,321-332.
14. Mechanisms of the Common Primary Hyperlipidaemias.
B. Lewis, A. Nicoll, E.D. Janus, R. Wootton and P. Turner (1978).
International Conference on Atherosclerosis edited by L.A. Carlson et al.
Raven Press, New York (1978) p 275-7.
15. Lipodystrophy with Hyperlipidaemia: The Role of Insulin in Very Low Density Lipoprotein Oversynthesis.
A. Chait, E.D. Janus, A.S. Mason and B. Lewis (1979).
Clin. Endocrinol. 10,173-178.
16. Kinetic Bases of the Primary Hyperlipidaemias:
Studies of Apolipoprotein B Turnover in Genetically Defined Subjects.
E.D. Janus, A.M. Nicholl, P.R. Turner, P. Magill and B. Lewis (1980).
Eur. J. Clin. Invest. 10,161-172.
17. Quantitative Studies of Very Low Density Lipoprotein (VLDL) Conversion to Low Density Lipoprotein (LDL) in Normal Controls and Primary Hyperlipidaemic States and the Role of Direct Secretion of LDL in Heterozygous Familial Hypercholesterolaemia.
E.D. Janus, A. Nicoll, R. Wootton, P.R. Turner, P.J. Magill and B. Lewis (1980).
Eur. J. Clin. Invest. 10,149-159.
18. The Antihypertensive Effect of Oral Verapamil - Acute and Long Term Administrations and its Effects of the High Density Lipoprotein Values in Plasma.
G.R.J. Lewis, D.J. Stewart, B.M. Lewis, P.J. Bones, K.D. Morley and E.D. Janus (1981).
Calcium antagonism in Cardiovascular Therapy. Experience with Verapamil. International Symposium, Florence 2 - 4 October, 1980.
Eds A. Zanchetti and D.M. Krikler.
Excerpta Medica Amsterdam Oxford Princeton p 270-279.
19. Blood Lipid Levels in Christchurch Blood Donors.
E.D. Janus, P.A. Suckling and M.R. Wardell (1981).
N.Z. Med. J. 94:114-115.
20. Genetic Variation in Human Apolipoprotein E.
M.R. Wardell, P.A. Suckling, and E.D. Janus (1982).
J. Lipid Res. 23:1174-1182.
21. In Vitro Synthesis of M and Z forms of Human Alpha-1-antitrypsin.
D.M. Errington, I.C. Bathurst, E.D. Janus and R.W. Carrell (1982).
FEBS Lett. 148:83-86.
22. Modes of action of Lipid-lowering diets in men: studies of apolipoprotein B kinetics in relation to fat consumption and dietary fatty acid composition.
C. Cortese, Y. Levy, E.D. Janus, P.R. Turner, S.N. Rao, N.E. Miller and B. Lewis (1983).
Eur. J. Clin. Invest. 13:79-85.
23. Hyperbetalipoproteinaemia and hyperalphalipoproteinaemia in a single family.
E.R. Nye, D.R.K. Harding, W.S. Hancock and E.D. Janus (1983).

- N.Z. Med. J. 96:85-88.
24. Red cell versus Whole blood Lead.
E.D. Janus, D. Hinton, B.M. Colls (1983).
N.Z. Med. J. 96:633-634.
 25. A register of Individuals with Inborn Errors of Lipoprotein Metabolism and their Families.
M.C. Robertson, E.R. Nye, E.D. Janus, W.H.F. Sutherland and E.R. Everest (1983).
N.Z. Med. J. 96:790-792.
 26. Lipoprotein Metabolism in Type III hyperlipoproteinaemia.
E.D. Janus, S. Grant, J. Bates and R. Wootton (1983).
Circulation 68, Suppl. III 290.
 27. Deconvolution in the Study of Lipoprotein Metabolism.
J.H.T. Bates and E.D. Janus (1983).
Australasian Physical and Engineering Sciences in Medicine 6:174-178.
 28. Familial and Genetic Data in Reflux Nephropathy.
R.R. Bailey, E.D. Janus, K. M^cLoughlin, K.L. Lynn and G.D. Abbott (1984).
In Hodson J (ed: "Contributions to Nephrology").
Basel " Karger 39:40-51.
 29. Management of Hypercholesterolaemia and Cholestyramine.
E.R. Nye, P.J. Scott and E.D. Janus (1984).
N.Z. Med. J. 97:272.
 30. Hyperlipidaemia: Drug or Non-drug Therapy?
E.D. Janus (1984).
New Ethicals 21:63-71.
Current Therapeutics 25:35-45.
 31. Industrial Lead Exposure. Review of Blood Lead Levels in South Island Industries 1974 - 83.
D. Hinton, B.C.L. Cresswell, E.D. Janus and W.A. Malpress (1984).
N.Z. Med. J. 97:769-773.
 32. Blood lead levels in the New Zealand population:
Preliminary communication W.A. Malpress, E.D. Janus and D. Hinton (1984).
N.Z. Med. J. 97:868-869.
 33. Smoking, Lung Function and Alpha-1-antitrypsin Deficiency.
E.D. Janus, N.T. Phillips and R.W. Carrell (1985).
Lancet. 1985 (i) 152-154.
 34. Preventing Ischaemic Heart Disease.
E.D. Janus (1985).
Journal of the New Zealand Dietetic Association.
39:24-26.
 35. Blood Lipids for the practising doctor.
E.D. Janus (1985).
National Heart Foundation of New Zealand Technical Report No. 42.

36. Vesicoureteric Reflux: Segregation Analysis.
C.J. Chapman, R.R. Bailey, E.D. Janus, G.D. Abbott and K.L. Lynn (1985).
Am. J. Med. Genet. 20:577-584.
37. Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatment.
E.D. Janus, S.J. Grant, C.J. Lintott and M.R. Wardell (1985).
Atherosclerosis 57:249-266.
38. The use of reversed-phase high performance liquid chromatography to analyse the cholesterol ester profiles present in lipoproteins of patients exhibiting hyperalphalipoproteinaemia or hypoalphalipoproteinaemia (Tangier Disease).
D. Poll, D.R.K. Harding, W.S. Hancock, E.R. Nye, E.D. Janus, S.F. Hannan and P.J. Scott (1985).
Journal of Chromatography 343:149-154.
39. Familial type V hypertriglyceridaemia in identical twin males homozygous for the apolipoprotein E2 variant. A clinical report, including response to treatment.
E.R. Nye, W.H.F. Sutherland and E.D. Janus (1986).
N.Z. Med.J. 96:146-149.
40. Apolipoprotein B metabolism in type III hyperlipoproteinaemia and in hypocholesterolaemic E2/2 subjects.
E.D. Janus, S. Grant, L. Sinclair and R. Wootton (1986).
In: N.H. Fidge and P.J. Nestel (Eds) "Atherosclerosis VII". *Excerpta Medica.* p 317-320.
41. Trends in blood lead level in Christchurch and environs 1974 - 84.
D. Hinton, P.A. Coope, W.A. Malpress and E.D. Janus (1986).
Journal of Epidemiology and Community Health
40:224-248.
42. Smoking, alpha-1-antitrypsin deficiency and emphysema.
E.D. Janus, N.T. Phillips and R.W. Carrell (1987).
In: J.C. Taylor and C. Mittman (Eds.). *Pulmonary emphysema and proteolysis". (Vol.II).* p 23-29.
43. Apo E2-Christchurch (136 Arg -> Ser): A new variant of human apolipoprotein E in a patient with Type III hyperlipoproteinaemia.
M.R. Wardell, S.O. Brennan, E.D. Janus, R. Fraser and R.W. Carrell (1987).
J. Clin. Invest. 80:483-490.
44. Inheritance of Vesicoureteric Reflux.
E.D. Janus (1988).
In: Schrier and Gottschalk (Eds) "Diseases of the kidney". 4th Edition
p 774-777.
45. Lead poisoning in automobile radiator mechanics.
E.D. Janus (1988).
N. Engl. J. Med. 318:321.
46. Cholesterol in the plasma very low density lipoprotein fraction in patients with type III hyperlipoproteinaemia. Analysis of factors which modulate its concentrations.
W.H. Sutherland, E.D. Janus, E.R. Nye and S. Grant (1988).
Biochem. Med. Metab. Biol. 39:305-311.

47. Alpha-1-antitrypsin Pi types in COPD.
E.D. Janus (1988).
Chest. 94:446-447.
48. The pathogenesis of atherosclerosis. New concepts in the area of lipids and lipoproteins.
E.D. Janus (1988).
Patient Management (Australia). 12:19-31.
49. Apolipoprotein A1 and B: Measurement and applications.
J.R.L. Masarei, G.D. Calvert and E.D. Janus (1988).
The Clinical Biochemist. 9:119-123.
50. Lipids and lipoproteins in patients undergoing coronary artery surgery.
T. Billington, E.D. Janus and H. Sinclair (1989).
Med. J. Aust. 150:302-306.
51. HMG CoA Reductase Inhibitors: Revolutionising therapy for hyperlipidaemias.
E.D. Janus (1989) & (1991).
Current Therapeutics. August 1989:43-51
Current Therapeutics. Cardiovascular Disease Special Issue.
January 1991:34-40.
52. Cholesterol lowering agents including new drugs
E.D. Janus (1989).
Australian Family Physician. 18:1071-1076.
53. Lipid, lipoproteins and apolipoproteins A-1 and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis.
J. Steele, T. Billington, E. Janus and J. Moran (1989).
Atherosclerosis. 79:47-50.
54. Apo E phenotypes and genotypes
T. Billington and E.D. Janus (1989).
Clinical Biochemist Monograph. "Advanced Electrophoretic Techniques in Clinical Diagnosis."
pp 44-46.
55. Apolipoprotein E2 - Dunedin (228 -> Arg Cys): an apo E2 variant with normal receptor binding activity.
M.R. Wardell, S.C. Rall Jr., S.O. Brennan, E.R. Nye, P.M. George, E.D. Janus and K.H. Weisgraber (1990).
J.Lipid Res. 31:535-543.
56. Alpha -1- antitrypsin deficiency and emphysema: New horizons in treatment.
E.D. Janus and J.W. Burdon (1990).
Aust. N.Z. J.Med. 20:755-757.
57. Treatment of Hyperlipidaemia.
E.D. Janus (1991).
In Cardiovascular Drug Guidelines (Victorian Drug Usage Advisory Committee):26-31.
58. Increased plasma apolipoprotein (a) levels in type I diabetic patients with microalbuminuria.
A.J. Jenkins, J.S. Steele, E.D. Janus & J.D. Best (1991).
Diabetes; 40:787-91.

59. Hyperlipidaemia: tips for GP^s
E.D. Janus (1991).
Patient Management. Dec 1991:39-42.
60. Alpha-1-antitrypsin deficiency:
Replacement therapy.
J.W.G. Burdon and E.D. Janus (1992).
Current Therapeutics 33:19-21.
Medical Progress (In press, November 1992)
61. Low density lipoprotein cholesterol and Lp(a) are higher when elaidic substitutes for oleic acid.
P. Nestel, M. Noakes, B. Belling, R. M^cArthur, P. Clifton, E. Janus and M. Abbey (1992).
J.Lipid Res. 33:1029-1036.
62. Alpha-1-antitrypsin replacement therapy - an early Australian experience.
J.W.G. Burdon, L. Cook, P. Holmes, E.D. Janus and S. Watts (1992).
Aust. N.Z. J. Med. 22:498-499.
63. Plasma Apolipoprotein(a) is increased in Type II Diabetic Patients with Microalbuminuria.
A.J. Jenkins, J.S. Steele, E.D. Janus, J.D. Santamaria and J.D. Best (1992).
Diabetologia 35:1055-1059.
64. Treatment of primary hypercholesterolaemia with pravastatin: efficacy and safety over three years.
L.A. Simons, P.J. Nestel, P. Clifton, E.D. Janus, J. Simons and A. Parfitt (1992).
Med. J. Aust. 157:584-589.
65. The prevalence and detection of lipid abnormalities in diabetes.
E.D. Janus (1992).
In Diabetic Dyslipidaemia an Australian Forum.
Reed Healthcare Communications 1992, 17-21.
66. Management of hyperlipidaemia in women and the elderly.
E.D. Janus (1992).
In Proceedings: ASEANZ Lipid Forum, Terrigal 26-28 June, 1992.
Excerpta Medica :24-27.
67. Prothrombin and antithrombotic factors are elevated in patients with type I diabetes complicated by microalbuminuria.
P. Lee, A. Jenkins, C. Bourke, J. Santamaria, C. Paton, E. Janus and J. Best (1993).
Diabetic Medicine 10:122-28.
68. Current issues in the treatment of dyslipidaemia.
E.D. Janus. Australian Family Physician (1993) 22:212-21.
69. Cholesterol lowering in women: Should they be treated any differently.
E.D. Janus (1993).
Heartbeat 8:4-6.
70. Apolipoprotein(a) and atherogenesis.
E.D. Janus (1993).
Pathology 25:291-293.

71. The Management of dyslipidaemia.
E.D. Janus (1993).
Journal of the Hong Kong College of Cardiology 1:124-129.
72. Simvastatin in severe primary hypercholesterolaemia: Efficacy, safety and tolerability in 595 patients over 18 weeks.
L.A. Simons on behalf of the principal investigators (including E.D. Janus) (1993).
Clin. Cardiol. 16:317-322.
73. Serum apolipoprotein(a) correlates with growth hormone levels in patients with acromegaly.
K.S.L. Lam, R.W.C. Pang, E.D. Janus, A.W.C. Kung and C.C.L. Wong (1993).
Atherosclerosis 104:183-188.
74. Homozygous Tangier disease and cardiovascular disease.
C. Serfaty-Lacrosniere, F. Civiera, A. Lanzberg, P. Isaia, J. Berg, E.D. Janus et al (1994).
Atherosclerosis 107:85-98.
75. Absence of alpha-1-antitrypsin (Pi Null Bellingham) and the early onset of emphysema.
L. Cook, E.D. Janus, E. Tai and J. Burdon (1994).
Aust NZ J Med 24:263-269.
76. Smoking and cardiovascular disease - known and potential mechanisms.
E.D. Janus (1994).
In Cardiovascular Disease: Current Perspectives on the Asian Pacific Region. Gardiner Caldwell Communications Ltd. Macclesfield, New Jersey, Hong Kong. 109-112.
77. Coronary heart disease and dyslipidaemia in Hong Kong. A survey of the knowledge and opinions of medical practitioners.
S.P. Wong, C. Cockram, E.D. Janus et al (1994).
J. Hong Kong Med. Assoc. 64:310-320.
78. Magnetic resonance imaging of cerebrotendinous xanthomatosis.
K.S. Tai, J. Brockwell, F.L. Chan, E. Janus and K. Lam (1995).
Australian Radiology 39:61-65.
79. Changes in serum lipoprotein (a) and lipids during treatment of hyperthyroidism.
A.W.C. Kung, R.W.C. Pang, I. Lauder, K.S.L. Lam and E.D. Janus (1995).
Clinical Chemistry 41:226-231.
80. Cholesterol lowering may retard the progression of diabetic nephropathy.
K.S.L. Lam, I.K.P. Cheng, E.D. Janus and R.W.C. Pang (1995).
Diabetologia 38:604-609.
81. Elevated serum lipoprotein(a) in subclinical hypothyroidism.
A.W.C. Kung, R.W.C. Pang and E.D. Janus (1995).
Clin. Endocrinol 43:445-449.
82. The case of the fisherman's lumps and bumps.
S.C.F. Tam, E.D. Janus, J. Brockwell, K.Y. Lam and A.C.L. Chan. (1995)
Med J Aust 163:652.
83. Alpha-1-antitrypsin P_{Lowell}: A normally functioning variant present in low concentration.
L. Cook, J. Burdon, S. Brenton and E.D. Janus (1995).

Aust NZ J Med 25:695-697.

84. Diet and lifestyle guidelines and desirable levels of risk factors for prevention of coronary heart disease in Indians
R.B. Singh, G.S. Sainani, S.S. Rastogi, S.V. Madhu, S. Krishnaswami, G.S. Wander, N.A. Shah, Rajeev Gupta, V. Shantaram, M.E. Yeolekar, Deepak Bhatnagar, A. Postiglione and E.D. Janus (1996)
J.InternMed7:
85. Frequency distribution of apolipoprotein(a) Kringle IV repeat alleles and their effects on Lp(a) levels in Caucasian, Asian and African populations: The distribution of null alleles is non-random.
H.G. Kraft, A. Lingenhel, R.W.C. Pang, R. Delport, M. Tromsdorff, H. Vermaak, E.D. Janus and G. Utermann (1996).
Eur. J. Hum. Genet 4:78-87.
86. Thyroid dysfunction in ambulatory elderly Chinese subjects in an area of borderline iodine uptake.
A.W.C. Kung and E.D. Janus.
Thyroid (1996) 6:111-114.
87. The prevalence of diabetes mellitus in elderly subjects in Hong Kong.
A.W.C. Kung and E.D. Janus (1996).
HKMJ 2:26-33.
88. Kinetic characterisation of alpha-1-antitrypsin F as an inhibitor of human neutrophil elastase.
L. Cook, J.G.W. Burdon, S. Brenton, K.R. Knight and E.D. Janus (1996).
Pathology 28:242-247.
89. Guide to plasma lipids and lipoproteins for Hong Kong doctors.
S.P. Wong, C.S. Cockram, E.D. Janus et al. (1996).
Journal of the Hong Kong College of Cardiology 4:81-89.
90. Lipid lowering drug therapy.
C.R. Kumana, K.S.L. Lam and E.D. Janus (1996).
Journal of the Hong Kong College of Cardiology 4:90-97 and
Medical Progress, September, 1997 : 5-11.
91. The modernization of Asia: Implications for coronary heart disease.
E.D. Janus, A. Postiglione, R.B. Singh and B. Lewis (1996).
Circulation 94:2671-2673.
92. Apolipoprotein(a) levels and phenotypes in NIDDM patients with microalbuminuria and albuminuria.
K.S.L. Lam, R.W.C. Pang, M.S. Wat, I.J. Lauder and E.D. Janus (1996).
Nephrology, Dialysis, Transplantation 11:2229-2236.
93. Indian Consensus for prevention of hypertension and coronary artery disease.
R.B. Singh, G.S. Sainani, S.S. Rastogi, S.V. Madhu, R. Beegom, G.S. Wander, N.A. Shah, S. Krishnaswami, M.E. Yeolekar, R. Gupta, V. Shantaram, S. Vajpayee, E.D. Janus, D. Bhatnagar, A. Postiglione, H. Mori, K.K. Sharma and R.K. Goyal (1996).
J. of Nutritional & Environmental Medicine 6, 309-318.
94. The prevalence of diabetes mellitus and thyroid diseases in the Hong Kong ambulant elderly population.

- E.D. Janus and A.W.C. Kung (1996).
Intern Med (Thailand) 12:61-62.
95. Lipid, lipoprotein and other biochemical parameters in the Hong Kong ambulant elderly population.
E.D. Janus, M.C. Lee and S.S. Cheung (1996).
Intern Med (Thailand) 12:96-98.
96. Growth hormone therapy increases apolipoprotein(a) in short beta-thalassaemia major children with normal growth hormone reserve.
S.C.F. Tam, R.W.C. Pang, E.D. Janus, E.Y.W. Kwan and L.C.K. Low (1997).
Atherosclerosis 128:175-182.
97. LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I.
K.C.B. Tan, S.W.M. Shiu and E.D. Janus (1997).
Atherosclerosis 129:59-65.
98. A modified sodium dodecyl sulphate-agarose gel/immunoblotting method for apolipoprotein(a) phenotyping using alkaline phosphatase-linked chemiluminescent detection.
R.W.C. Pang, E.D. Janus, K.S.L. Lam, A. Lingenhel and H.G. Kraft (1997).
Ann Clin Biochem 34:314-316.
99. Frequency distributions of plasma apolipoprotein(a) levels and phenotypes: A comparison between Southern and Northern Chinese populations.
R.W.C. Pang, B.S. Chen, E.D. Janus and K.S.L. Lam (1997).
Chinese Medical Journal 110:465-473.
(Commemorative Hand Over Issue).
100. The Hong Kong Cardiovascular Risk Factor Prevalence Study 1995 - 1996.
Janus E.D. for the Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee, (1997). In Book Form. ISBN 962-8310-03-8.
101. The Hong Kong Adult Dietary Survey 1995 - 1996.
Leung S.S.F., Ho S.C., Woo J., Lam T.H. and Janus E.D. (1997) in Book Form. ISBN 962-8310-02-X.
102. Dietary practices and lipid intake in relation to plasma lipid profile in Hong Kong Chinese.
Woo J., Leung S.S.F., Ho S.C., Sham A., Lam T.H. and Janus E.D (1997).
Eur J Clin Nutr 51:467-471.
103. Treatment of hyperlipidaemia in NIDDM patients with progressive nephropathy.
I.K.P. Cheng, K.S.L. Lam, E.D. Janus, R.W.C. Pang and I.J. Lauder (1997).
Contrib Nephrol. Basel, Karger 120:79-87.
104. The Modernization of Asia. Implications for coronary heart disease
E.D. Janus, A. Postiglione, R.B. Singh, B. Lewis on behalf of the ISFC
Scientific Council on Arteriosclerosis (1997).
Heart Beat 1997-2:1-3.
105. Chapters in "The Health of the Elderly in Hong Kong". Hong Kong University Press, Editor S.K. Lam (1997). ISBN 962-204-4317.
(a) Lipids, lipoprotein and other biochemical and haematological parameters in the elderly in Hong Kong.
E.D. Janus, M.C. Lee and S.S. Cheung.

Chapter 8:111-128.

- (b) Height, weight tables for Hong Kong elderly men and women.
L.W. Chu, S.K. Lam, E.D. Janus, A.W.C. Kung, C.P. Lau, E.M.F. Leung, M.B.M. Lo.
Chapter 9:129-138.
 - (c) Thyroid dysfunction in ambulatory Chinese subjects over the age of 60.
A.W.C. Kung and E.D. Janus
Chapter 10:139-146.
 - (d) The prevalence of diabetes mellitus in elderly subjects in Hong Kong.
A.W.C. Kung and E.D. Janus
Chapter 11:147-160.
106. The proteinase-antiproteinase theory of emphysema: a speculative analysis of recent advances into the pathogenesis of emphysema.
K.R. Knight, J.G.W. Burdon, L. Cook, S. Brenton, M. Ayad and E.D. Janus (1997).
Respirology 2:91-95.
107. The effect of radioiodine treatment of hyperthyroidism on apolipoprotein(a) levels and phenotypic expression.
E.D. Janus, R.W.C. Pang, D.T. Chua, C.C. Yau, A.W.C. Kung and K.S.L. Lam (1997).
Endocrinology and Metabolism 4:353-360.
108. The Epidemiology of Cardiovascular Risk Factors in Hong Kong.
Janus E.D. for the Hong Kong Cardiovascular Risk Factor Prevalence Study Group (1997).
Proceedings of Inaugural Scientific Meeting of the Institute of Cardiovascular Medicine and Science, The University of Hong Kong.
Clinical and Experimental Pharmacology and Physiology 24:987-988.
109. Lipoprotein(a): A new risk factor in coronary heart disease.
E.D. Janus and R.W.C. Pang (1997).
JAMA Southeast Asia 13:12/5-6.
110. A food frequency questionnaire for use in the Chinese population in Hong Kong: Description and validation.
Woo J., Leung S.S.F., Ho S.C., Lam T.H. and Janus E.D (1997).
Nutrition Research 17:1633-1641.
111. Plasma total antioxidant capacity in an adult Hong Kong Chinese population.
J. Woo, S.S.F. Leung, C.W.K. Lam, S.C. Ho, T.H. Lam and E.D. Janus (1997).
Clin. Biochem. 7:553-557.
112. Hong Kong adult dietary survey, 1995.
S.S.F. Leung, J.Woo, S.Ho, T.H Lam and E.D. Janus (1998)
Aust J Nutr Diet 55 [1suppl]:S11-S13
113. Plasma ascorbate and vitamin E levels in Hong Kong Chinese.
I.F.F. Benzie, E.D. Janus, J.J. Strain (1998)
Eur J Clin Nutr 52: 447-451.

114. Genetic influence on factor VII activity is overwhelmed by environmental factors in Chinese patients with non-insulin dependent diabetes mellitus.
K.S.L. Lam, O.G.K. Ma, C. Bourke, L.C. Chan and E.D. Janus (1998).
Diabetologia 41 : 760-766.
115. Dietary Intake and Practices in the Hong Kong Chinese population.
Woo J., Leung S.S.F., Ho S.C., Lam T.H. and Janus E.D (1998).
J. Epidemiol Community Health 52 : 631-637.
116. The Modernization of Asia - implications for coronary heart disease. In Proceedings of Asian Clinical Trials Conference, 1998.
E.D. Janus (1998).
Acta Pharmacologica Sinica 19 Suppl : 6-8.
117. Chapter in "Introduction to Clinical Trials. Clinical Trials Methodology. Statistical Methods in Clinical Trials. The ICH GCP Guidelines". The Clinical Trials Centre, University of Hong Kong. Editors J. Karlberg and K. Tsang (1998) ISBN 962-85405-13.

Clinical Trials Study Documents
E.D. Janus (1998)
Chapter 1.5 : 66-72.
118. Near - patient testing for serum cholesterol: attitudes of general practitioners and patients, appropriateness, and costs.
E.D. Janus, J.D. Parkin, I.S. Ratnaike and H.G. Schneider (1999).
Med J Aust 170: 187-188.
119. The relationship between fibrinogen and other coronary heart disease risk factors in a Chinese population.
T.H. Lam, L.J. Liu, E.D. Janus, C. Bourke and A.J. Hedley (1999).
Atherosclerosis 143:405-413.
120. Influence of educational level and marital status on dietary intake, obesity and other cardiovascular risk factors in a Chinese population.
J. Woo, S.S.F. Leung, S.C. Ho, A. Sham, T.H. Lam and E.D. Janus (1999)
Eur J Clin Nutr 53:461 – 467.
121. β -fibrinogen gene G/A-455 polymorphism in relation to fibrinogen levels and ischaemic heart disease in Chinese patients with type 2 diabetes.
K.S.L. Lam, O.C.K. Ma, N.M.S. Wat, C. Bourke, L.C. Chan and E.D. Janus (1999).
Diabetologia 42:1250-1253.
122. Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus.
K.C.B. Tan, E.D. Janus, K.S.L. Lam (1999).
Am J Cardiol 84:934 – 937.
123. The Hong Kong Cardiovascular Risk Factor Prevalence Study 1995-1996
E.D. Janus (1999).
Proceedings of the Victorian Heart Centre pp100 – 102.
124. Fibrinogen, angina and coronary heart disease in a Chinese population.
T.H. Lam, L.J. Liu, E.D. Janus, C.P. Lau and A.J. Hedley (2000).
Atherosclerosis 149:443 – 449.

125. The Prevalence of Diabetes, Association with Cardiovascular Risk Factors and Implications of Diagnostic Criteria (ADA 1997 and WHO 1998) in a 1996 Community Based Population Study in Hong Kong Chinese.
E.D. Janus, N.M.S. Wat, K.S.L. Lam, C.S. Cockram, S.T.S. Siu, L.J. Liu and T.H. Lam (2000).
Diabet. Med 17:741 – 745.
126. Intake of soy products is associated with better plasma lipid profiles in the Hong Kong Chinese population.
S C Ho, J Woo, S.S.F. Leung, A. Sham, T.H. Lam and E.D.Janus (2000).
J Nutr 130:2590 - 2593.
127. Fibrinogen, other cardiovascular risk factors and diabetes mellitus in Hong Kong: a community with a high prevalence of non – insulin dependent diabetes and impaired glucose tolerance.
T.H. Lam, L.J. Liu, E.D. Janus, K.S.L. Lam and A.J. Hedley(2000)
Diabet. Med 17:798 – 806.
128. Burgeoning Atherosclerosis in Asia (Invited Editorial)
E. D. Janus (2000).
Heart, Lung and Circulation 9:60.
129. A simple HPLC cotinine assay: validation of smoking status in pregnant women.
R.Greaves, L.Trotter, S.Brennecke and E.D.Janus (2001).
Ann Clin Biochem 38:333- 338.
130. Dietary habits of smokers in a Chinese population.
J.Woo, S.C.Ho, A. Sham, S.S.F.Leung, T.H.Lam and E.D.Janus (2001).
Int J Food Sci Nutr 52:477 - 484.
131. Association between simple anthropometric indices and cardiovascular risk factors.
S C Ho, Y M Chen, J L F Woo, S S F Leung, T H Lam and E D Janus (2001).
Int J Obes Related Metab Disord 25:1689 – 1697.
132. Sodium is the Leading Dietary Factor Associated with Urinary Calcium Excretion in Hong Kong Chinese Adults.
S.C.Ho, Y.M. Chen, J.L.F. Woo, S.S.F./Leung, T.H.Lam and E.D.Janus (2001).
Osteoporosis Int 12:723 – 731.
133. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO - 2 randomised trial.
The hirulog and Early Reperfusion or Occlusion (HERO) –2 Trial Investigators (including E.D.Janus & M. O’Sullivan) (2001).
Lancet 2001; 358: 1855 – 63.
134. Central obesity predicts the worsening of glycaemia in Southern Chinese.
N.W.Wat, T.H.Lam, E.D.Janus and K.S.L.Lam (2001).
Int J Obes Related Metab Disord 25:1789-93.
135. Decline in FEV1 in patients with PiZ alpha-1-antitrypsin deficiency: The Australian experience
J.W.G Burdon, S Brenton, V Hocking, K.R.Knight, M Ayad, L Cook and E.D.Janus (2002).
Respirology 7: 51 – 55.

136. Smoking, alcohol drinking and non-fatal coronary heart disease in Hong Kong Chinese. T.H.Lam, S.F.Chung, E.D.Janus, C.P.Lau, A.J.Hedley, H.W.Chan, L.Chow, K.K.Keung and S.K.Li (2002).
Annals of Epidemiology 2002;12:560-7.
137. Prevalence and correlates of alcohol use: a population based study in Hong Kong. M Janghorbani, SY Ho, TH Lam and ED Janus (2003).
Addiction 98(2):215-224.
138. Effects of a promotor variation in the hepatic glucokinase gene on promotor activity and glucose tolerance in Southern Chinese subjects. M. Zhang, K.C.B. Tan, W-Y. Zhang, J-Y. Xu, N.M.S. Wat, S.S.M. Chung, E.D. Janus and K.S.L. Lam (2003).
Clinical Genetics 2003;63:232-234.
141. Smoking and perceived health in Hong Kong Chinese. S.Y. Ho, T.H.Lam, R. Fielding and E.D.Janus (2003).
Soc Sci Med 57;1761 - 1770.
142. The emergence of coronary heart disease in populations of Chinese descent. T.Dwyer, S.C.Emmanuel, E.D. Janus, Wu Zhaosu, Zhang Changmin, K.L.Hynes (2003).
Atherosclerosis 167;303-310..
143. Lipids and Coronary Heart Disease in Asia. KL Khoo, H Tan, YM Liew, JP Deslypere and ED Janus (2003)
Atherosclerosis 169; 1-10.
144. C-Reactive Protein predicts the deterioration of glycaemia in Chinese subjects with impaired glucose tolerance. KCB Tan, NMS Wat, SCF Tam, ED Janus, TH Lam and KSL Lam (2003).
Diabetes Care 26: 2323-2328.
145. Waist to stature ratio is more strongly associated with cardiovascular risk factors than other anthropometric indices. SY Ho, TH Lam and ED Janus (2003).
Ann Epidemiol 2003;13:683-691.
146. Association between total and beverage-specific alcohol intake and obesity and fat distribution: a population – based study in Hong Kong. M Janghorbani, SY Ho, TH Lam and ED Janus (2003).
Alcohol Research 8; 263 – 27.
147. Diet and glucose tolerance in a Chinese population. J Woo, SC Ho, A Sham, MM Shea, KSL Lam TH Lam and ED Janus (2003).
European Journal of Clinical Nutrition 57; 523 – 530.
148. Metabolic syndrome and its relevance to Asian countries. E D Janus (2004).
Atherosclerosis XIII Proceedings (Elsevier) 535-537.
149. Childhood Migration and Cardiovascular Risk. TH Lam, M Schooling and ED Janus (2004).
Int J Epidemiol 33:1219-26.

150. Subjective health and fibrinogen in a healthy Chinese cohort.
R Fielding, TH Lam, SY Ho, ED Janus (2004).
Br J Health Psychol. 9:523-32.
151. Impact of obesity and body fat distribution on cardiovascular risk factors in a Chinese population: the Hong Kong Cardiovascular Risk Factor Prevalence Study.
GN Thomas, S-Y Ho, KSL Lam, ED Janus, AJ Hedley, TH Lam for the Hong Kong Cardiovascular Risk Factor Prevalence Study Steering committee (2004).
Obesity Res 12:1805 -13.
152. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population.
GN Thomas, S-Y Ho, ED Janus, KSL Lam, AJ Hedley, TH Lam for the Hong Kong Cardiovascular Risk factor Prevalence Study Steering Committee (2005).
Diabetes Res Clin Pract 67:251-257.
153. Is a single definition of the Metabolic syndrome appropriate? – a comparative study of the USA and Asia.
A Patel, KC Huang, E Janus, T Gill, B Neal, P Suriyawongpaisal, E Wong, M Woodward and RP Stolk (2006).
Atherosclerosis 184:225-232.
154. Plasma lipid, lipoprotein and apolipoprotein levels in a random population sample of 2875 Hong Kong Chinese adults and their implications (NCEP ATP-III, 2001 guidelines) on cardiovascular risk assessment.
Richard W.C. Pang, Sidney C.F. Tam, Edward D. Janus, Simon T.S. Siu, Oliver C.K.Ma, T.H. Lam and Karen S.L. Lam. (2006).
Atherosclerosis 184:438-445.
155. Impact of gender-specific body composition on cardiovascular risk factors: the Hong Kong Cardiovascular Risk factor Study.
GN Thomas, SM McGhee, M Schooling, SY Ho, KSL Lam, ED Janus, TH Lam for the Hong Kong Cardiovascular Risk factor Prevalence Study Steering committee (2006).
Endocrinology and Metabolism.Clinical and Experimental 55:563-569.
156. Polymorphisms of the Gene Encoding Adiponectin and Glycaemic Outcome of Chinese Subjects with Impaired Glucose Tolerance: a 5 year Follow-up Study.
AWK Tso, PC Sham, NMS Wat, A Xu, BMY Cheung, R Rong, CHY Fong, JY Xu, KKY Cheung, ED Janus and KSL Lam (2006).
Diabetologia 49:1806-15.
157. Determinants of normoglycaemia and contribution to cardiovascular risk factors in a Chinese population: The Hong Kong Cardiovascular Risk Factor Study.
GN Thomas, SM McGhee, M Schooling, SY Ho, KSL Lam, ED Janus, TH Lam for the Hong Kong Cardiovascular Risk factor Prevalence Study Steering Committee (2006).
J Endocrinol Invest. 29:528-535.
158. Endothelial Nitric Oxide Synthase G894T (Glu298Asp) polymorphism was predictive of glycaemic status in a 5 year prospective study of Chinese subjects with impaired glucose tolerance.
AWK Tso, KCB Tan, NMS Wat, ED Janus, TH Lam, KSL Lam (2006).
Metabolism 55:1155-58.

159. Identification of factors differentially associated with isolated impaired fasting glucose and isolated post-load impaired glucose tolerance: the Hong Kong Cardiovascular Risk Factor Study. GN Thomas, C M Schooling, SM McGhee, SY Ho, BMY Cheung, NMS Wat, ED Janus, TH Lam for the Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee (2006). *European Journal of Endocrinology* 155:623-32.
160. Predictors of the Development of Hypertension in The Hong Kong Cardiovascular Risk Factor Prevalence Study – 2 (CRISPS2) BMY Cheung, NMS Wat, YB Man, SCF Tam, CH Cheng, GM Leung, J Woo, ED Janus, CP Lau, TH Lam, KSL Lam (2006). *J Hypertens* 2006; 24 Suppl 6:123.
161. Resistin gene polymorphism and progression of glycaemia in Chinese: a 5-year prospective study. JY Xu, PC Sham, A Xu, AWK Tso, NMS Wat, KY Cheng, CHY Fong, ED Janus and KSL Lam.(2007). *Clin Endocrinol* 66:211-217.
162. Is height associated with cardiovascular risk in Chinese adults? CM Schooling, GN Thomas, GM Leung, SY Ho, ED Janus, KSL Lam, TH Lam for the Hong Kong Cardiovascular Risk factor Study Steering committee (2007). *Epidemiology* 18:274-278.
163. Prevention of Type 2 Diabetes in a primary health care setting. Interim results from the Greater Green Triangle (GGT) Diabetes Prevention Project. Annamari Kilkinen, Sami Heistaro, Anna Chapman, Tiina Laatikainen, Pilvikki Absetz, Edward Janus, James Dunbar (2007). *Diabetes Res Clin Pract* 76:460-462.
164. The relation of chronic cardiovascular diseases and diabetes mellitus to perceived health, and the moderating effects of sex and age. SY Ho, KK Mak, G N Thomas, M Schooling, R Fielding, ED Janus and TH Lam (2007). *Soc Sci Med* 65:1386-1396.
165. Greater Green Triangle Risk Factor Study. Limestone Coast and Corangamite Shire Surveys. Basic report. S Heistaro, E Janus, J Dunbar, T Laatikainen, A Kilkinen (2007). Published by Deakin University Press. Pages 1-199.
166. Development of Diabetes in Chinese with the Metabolic Syndrome – a Six Year Prospective Study. BMY Cheung, , NMS Wat, YB Man, SCF Tam, GN Thomas, GM Leung, CH Cheng, J Woo, ED Janus, CP Lau, TH Lam, KSL Lam (2007). *Diabetes Care* 30:1430-6.
167. Serum adipocyte fatty acid-binding protein as a new biomarker for the risk of type 2 diabetes – a 10 year prospective study in Chinese. AWK Tso, A Xu, PC Sham, NMS Wat, Yu Wang, CHY Fong, BMY Cheung, ED Janus, KSL Lam (2007). *Diabetes Care* 30(10):2667-72.
168. Circulating adipocyte-fatty acid binding protein levels predicted the development of the metabolic syndrome in a five-year prospective study.

A Xu, AWK Tso, BMY Cheung, Y Wang, NMS Wat, C Fong, ED Janus, KSL Lam (2007)
Circulation 115:1537-1543.

169. Metabolic Syndrome increases all-cause and vascular mortality: The Hong Kong Cardiovascular Risk Factor Study.
G Neil Thomas, C Mary Schooling, Sandra M McGhee, Sai-Yin Ho, Bernard MY Cheung, Nelson MS Wat, Edward D Janus, Karen SL Lam, Tai Hing Lam for the Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee (2007).
Clinical Endocrinology 66:666-671.
170. Hypoadiponectinemia is Predictive of the Development of hypertension.
WS Chow, BMY Cheung, AWK Tso, A Xu, NMS WAT, CHY Fong, S Tam, KCB Tan, ED Janus, TH Lam, KSL Lam (2007).
Hypertension 49:1-7.170.
171. Overweight, obesity and metabolic syndrome in rural south eastern Australia
E D Janus, T Laatikainen, J Dunbar, A Kilkinen, SJ Bunker, B Philpot, P Tideman, R Tirimacco, S Heistaro (2007).
Med J Aust 187:147-152.
172. Components of the Metabolic Syndrome Predictive of its Development:A Six Year Longitudinal Study in Hong Kong Chinese.
BMY Cheung, NMS Wat, S Tam, GN Thomas, GM Leung, CH Cheng, J Woo, ED Janus, CP Lau, TH Lam, KSL Lam (2007).
Clin Endocrinol 68:730-737.
- 173*. Prevention of Type 2 Diabetes by lifestyle intervention in an Australian primary health care setting: Greater Green Triangle (GGT) Diabetes Prevention Project.
T Laatikainen, JA Dunbar, A Chapman, A Kilkinen, E Vartiainen, S Heistaro, B Philpot, P Absetz, S Bunker, A O'Neil, P Reddy, JD Best, E D Janus (2007).
BMC: Public Health 7:249 doi:10.1186/1471-2458-7-249
- 174*. Growth environment and sex differences in lipids, body shape and diabetes risk.
C Mary Schooling, Tai Hing Lam, G Neil Thomas, Benjamin J Cowling, Mivchelle Heys, Edward D Janus, Gabriel M Leung for the Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee (2007).
PLoS ONE.2007 Oct 24;2(10):e1070.
175. Waist circumference thresholds provide an accurate and widely applicable method for the discrimination of diabetes.
Obesity in Asia Collaboration: R Huxley, F Barzi, CMY Lee et al. E D Janus as a principal collaborator.(2007)
Diabetes Care Dec 2007;30; 12:3116-3118.
176. Is central obesity a better discriminator of the risk of hypertension than body mass index in ethnically diverse populations?
The Obesity in Asia Collaboration: R Huxley, F Barzi, CMY Lee, E Janus, TH Lam, I Caterson, F Azizi, S Lear, J Patel, J Shaw, J Adam, SW Oh, JH Kang, P Zimmet, M Woodward (2008).
Journal of Hypertension 26:169-177.
177. Physical activity behaviours of adults in the Greater Green Triangle region of rural Australia.
C Vaughan, A Kilkinen, B Philpot, J Brooks, A Schoo, T Laatikainen, A Chapman, E D Janus and J A Dunbar (2008).
Aust J Rural Health 16:92-99.

178. The prevalence, detection and treatment of Hypertension in Rural Australia.
E D Janus, SJ Bunker, K Mc Namara, TK Laatikainen, AM Kilkkinen, S Heistaro, B Philpot and JA Dunbar (2008).
Internal Medicine Journal 38:879-886.
179. Coordinated anticoagulation management in a rural setting.
Kathleen Hodge, Edward Janus, Vijaya Sundararajan, Sally Taylor, Wendy Brand, Joseph Ibrahim and Alan Wolff (2008).
Australian Family Physician 37:280-283.
180. Relationship between the metabolic syndrome and the development of hypertension in the Hong Kong Cardiovascular Risk Factor Study - 2 (CRISPS2)
BMY Cheung, NMS Wat, YB Man, S Tam, CH Cheng, GM Leung, J Woo, ED Janus, CP Lau, TH Lam, KSL Lam (2008).
American Journal of Hypertension 21: 17-22.
181. Association between plasma alkaline phosphatase and C-reactive protein in Hong Kong Chinese.
Bernard M Y Cheung, Kwok Leung Ong, Roberta V Cheung, Louisa Y F Wong, Nelson M S Wat, Sidney Tam, Gabriel M Leung, Chun Ho Cheng, Jean Woo, Edward Janus, Chu Pak Lau, Tai Hing Lam and Karen S L Lam (2008).
Clin Chem Lab Med 46(4):523-527.
182. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension
R Huxley, W P T James, F Barzi, J V Patel, S A Lear, P Suriyawongpaisal, E Janus, I Caterson, P Zimmet, D Prabhakaran, S Reddy, M Woodward on behalf of the Obesity in Asia Collaboration (2008)
Obesity reviews 9 (Suppl.1), 53-61.
183. BMI compared with central obesity indicators in relation to diabetes and hypertension in Asians
R Nyamdorj, Q Qiao, TH Lam, J Tuomilehto, SY Ho, J Pitkaniemi, T Nakagami, V Mohan, E D Janus and SRG Ferriera for the DECODA Study Group (2008).
Obesity 16: 1622 -1635.
184. Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese.
BMY Cheung, NMS Wat, AWK Tso, S Tam, GN Thomas, GM Leung, HF Tse, J Woo, ED Janus, CP Lau, TH Lam, KSL Lam (2008)
Diabetes Care 31:1889-1891.
185. Depression: an important co-morbidity with metabolic syndrome in a general population.
J Dunbar, P Reddy, N Davis-Lameloise, B Philpot, T Laatikainen, A Kilkkinen, S Bunker, J Best, E Vartiainen, S Lo, E Janus (2008).
Diabetes Care 31:2368-2373.
186. Depression in acute coronary syndrome: Has the evidence been implemented?
P Reddy, JA Dunbar, A O'Neill, MA Morgan, AM Wolff and ED Janus (2008).
Aust J Rural Health 16: 245-246.
187. Caution is advised in the treatment of chronic hyponatraemia.
C Do, M Anpalahan, E Janus (2008).
Internal Medicine Journal (Letter to the editor) 38:929-930.

188. Chronic disease risk factors in rural Australia – results from the Greater Green Triangle Risk Factor Surveys.
T Laatikainen, E Janus, A Kilkkinen, S Heistaro, P Tideman, A Baird, R Tirimacco, M Whiting, L Franklin, A Chapman, A Kao-Philpot and J Dunbar (2009).
Asian Pac J Public Health 21:51-62.
189. High density lipoprotein-cholesterol levels increase with age in American women but not in Hong Kong Chinese women.
BMY Cheung, MF Li, KL Ong, NMS Wat, SCF Tam, RW Pang, GN Thomas, GM Leung, CH Cheng, J Woo, ED Janus, CP Lau, TH LAM, KSL Lam (2009).
Clinical endocrinology 70:561-568.
190. A socio-historical hypothesis for the diabetes epidemic in Chinese - preliminary observations from Hong Kong as a natural experiment.
M Schooling, TH Lam, ED Janus, BJ Cowling, GM Leung for the Hong Kong cardiovascular Risk factor Prevalence study steering committee (2009).
American Journal of Human Biology 221:346-353.
191. Rural Smokers: A prevention opportunity.
Anna Chapman, Stephen Bunker, James A Dunbar, Kevin McNamara, Ben Philpot, Andrew Baird, Annamari Kilkinnen, Tiina Laatikainen and Edward Janus(2009).
Australian Family Physician 38:352-356.
192. How population health data can help primary care services to improve population health - a rural case study.
K Mc Namara, JA Dunbar, P Reddy, B Philpot C Vaughan, M Morgan, E Janus (2009).
Public Health Bulletin SA 6:21-25.
193. The discrimination of dyslipidaemia using anthropometric measures in ethnically diverse populations of the Asia Pacific Region: The Obesity in Asia Collaboration
F Barzi, M Woodward, S Czernichow, C Lee, JH Kang, E Janus, S Lear, I Catterson, J Patel, TH Lam, P Suriyawongpaisal, R Huxley - the Obesity in Asia Collaboration (2009).
Obesity reviews 30 March 2009 doi:10.1111/j.1467-789X.2009.00605.x.
194. The association of levels of physical activity with metabolic syndrome in rural Australian adults.
C Vaughan, A Schoo, E D Janus, B Philpot, N Davis-Lameloise, S K Lo, T Laatikainen, E Vartianen, J A Dunbar (2009).
BMC Public Health 2009,9:273 doi:10.1186/1471-2458-9-273
195. Blood lipid levels in relation to glucose status in seven populations of Asian origin without a prior history of diabetes: the DECODA Study
L Zhang, Q Qiao, J Tuomilehto, N Hammar, E D Janus, S Soderberg, V Mohan, A Ramachandran, YH Dong, TH Lam, ZC Pang for the DECODA Study Group (2009).
Diabetes/Metabolism Research and Reviews 25:549-557.
196. Ethnic comparison of the association of undiagnosed diabetes with obesity.
R Nyamdorj, J Pitkaniemi, J Tuomilehto, N Hammar, CDA Stehouwer, TH Lam, A Ramachandran, ED Janus, V Mohan, S Soderberg, T Laatikainen, G Rafael and Q Qiao for the DECODA and DECODE study Groups (2009).
Int J of Obesity 3 November 2009; doi:10.1038/ijo.2009.225. 194*.

197. The Greater Green Triangle Diabetes Prevention Project: Remaining Treatment Gaps in Hypertension and Dyslipidaemia.
K McNamara, B Philpot, E D Janus, J A Dunbar (2010).
Aust J Rural Health 18:43-44.
198. Should capillary blood glucose measurements be used in population surveys?
R Tirimacco, P Tideman, J Dunbar, P Simpson, B Philpot, T Laatikainen, E Janus (2010).
International Journal of Diabetes Mellitus. Published on line 7 January 2010
doi:10.1016/j.ijdm.2009.12.002.
199. Dyslipidaemia in rural Australia: Prevalence, awareness and treatment gaps.
E D Janus, P A Tideman, J A Dunbar, A Kilkinen, S J Bunker, B Philpot, R Tirimacco, K McNamara, S Heistaro and T Laatikainen (2010).
Med J Aust 192:127-132.
200. Distinct ethnic differences in lipid profiles across glucose categories.
L Zhang, Q Qiao, J Tuomilehto, ED Janus, TH Lam, A Ramachandran, V Mohan, CDA Stehouwer, Y Dong, T Nakagami, A Onat, S Soderberg, A Abu Sayeed for the DECODE/DECODA Study Group (2010).
Journal of Clinical Endocrinology and Metabolism. Published on line 29 January 2010;
doi:10.1210/jc.2009-2348.
201. Obesity susceptibility genetic variants identified from recent genome-wide association studies: implications in a Chinese population.
CYY Cheung, AWK Tso, BMY Cheung, A Xu, KL Ong, CHY Fong, NMS Wat, ED Janus, PC Sham, KSL Lam (2010).
Journal of Clinical Endocrinology and Metabolism. Published on line 8 January 2010: doi 10.1210/jc.2009-1465.
202. Does abnormal insulin action or insulin secretion explain the increase in prevalence of IGT with age in populations of different ethnicities?
F Ning, Q Qiao, J Tuomilehto, N Hammar, SY Ho, S Soderberg, PZ Zimmet, JE Shaw, T Nakagami, V Mohan, A Ramachandran, TH Lam, SW Andersson, ED Janus, J Boyko, W Fujimoto for the DECODA Study Group. (2010).
Diabetes/Metabolism, Research and Reviews 26:245-253.
203. Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidaemic and hyperlipidaemic subjects.
EMM Ooi, ED Janus, SJ Grant, LMT Sinclair, PHR Barrett(2010).
Journal of Lipid Research 51:2413-2421.
204. An epidemiological analysis of risk factors: rural versus metropolitan – are there differences? A comparison between the North West Adelaide Health Study and the Greater Green Triangle Risk Factor Study.
A Montgomerie, P Tideman, A Taylor, E Janus, B Philpot, R Tirimacco, T Laatikainen, S Heistaro, J Grant, E Vartainen and J Dunbar (2010).
Population Research and Outcome Studies Unit, SA Health, Adelaide and Greater Green Triangle University Department of Rural Health, Flinders and Deakin Universities.
ISBN 9780730898764.
205. Sustained gains from a diabetes prevention program and the role of telephone support.
JA Dunbar, N Davis-Lameloise, B Philpot, P Reddy, S Bunker, S Heistaro, T Laatikainen and E D Janus (2010).

206. Communication between primary and secondary care centres. The results of the planning phase of a quality improvement study.
M Anpalahan and E D Janus (2010)
Australian Association for Quality in Health Care Journal 20:22-27.
- 207*. Plasma level of pigment epithelium-derived factor is independently associated with the development of the metabolic syndrome in Chinese men: a 10 year prospective study.
C Chen, AWK Tso, LSC Law, BMY Cheung, KL Ong, NMS Wat, ED Janus, A Xu, KSL Lam (2010).
Journal of Clinical Endocrinology and Metabolism (accepted 13 July 2010 - in proof then on line)
- 208*. Diabetes research and clinical practice.
JA Dunbar, P Reddy, K McNamara, ED Janus (2010).
Diab Res Clin Pract (2010), doi;10.1016/j.diabres.2010.05.015 (Letter).
- 209*. Engaging community pharmacists in the primary prevention of cardiovascular disease: protocol for the Pharmacist Assessment of Adherence, Risk and Treatment in Cardiovascular Disease (PAART CVD) pilot study (2010).
KP McNamara, G Johnson, SL O'Reilly, SL Jackson, GM Peterson, H Howarth, MJ Bailey, G Duncan, P Trinder, E Morabito, J Finch, S Bunker, E Janus, J Emery, JA Dunbar (2010).
BMC Health Services Research 2010, **10**:264 doi:10.1186/1472-6963-10-264.
- 210*. The projected impact of population and high risk strategies for risk factor control on coronary heart disease and stroke events.
EA Vartiainen, T Laatikainen, B Philpot, ED Janus, N Davis-Lameloise, JA Dunbar(2010).
Med J Aust (in press).
211. Greater Green Triangle Diabetes Prevention Program: remaining treatment gaps in hypertension and dyslipidaemia.
K McNamara, B Philpot, ED Janus, JA Dunbar (2010).
Australian Journal of Rural Health 18:43-44.

PAPERS DELIVERED AT CONFERENCES AND MEETINGS:***(PRESENTER)**

1. Human Genetics Society of Australasia, Queenstown, N.Z., 1979.
 - (i) Alpha-1-antitrypsin deficiency - E.D. Janus.
 - (ii) Familial hypercholesterolaemia - E.D. Janus.
2. 5th International Symposium on Atherosclerosis, Houston, Texas, U.S.A., November, 1979. Studies of apolipoprotein B kinetics in genetically determined primary hyperlipidaemias. E.D. Janus*, P.R. Turner, A.M. Nicoll and B. Lewis.
3. Medical Research Council Symposium on Genetically determined Diseases, Dunedin, New Zealand, February 1980.
 - (i) Alpha-1-antitrypsin deficiency - E.D. Janus.
 - (ii) Familial hypercholesterolaemia - E.D. Janus.
4. Timaru (N.Z.) Medical Postgraduate Society Meeting, August 1980. Management of the hyperlipidaemic subjects. E.D. Janus
5. West Coast (N.Z.) Medical Postgraduate Society, November 1980. Hyperlipidaemias and Atherosclerosis. E.D. Janus.
6. Australian Atherosclerosis Meeting, Adelaide, May 1981. Genetic variation in human apolipoprotein E. E.D. Janus*, M.R. Wardell and P.A. Suckling.
7. Human Genetics Society of Australasia, Canberra, May 1981. Genetic variation in human apolipoprotein E. E.D. Janus*, M.R. Wardell and P.A. Suckling.
8. N.Z.A.C.B. Conference, Christchurch, N.Z., September 1981. An update on hyperlipidaemias. E.D. Janus (by invitation).
9. Canterbury Medical Research Foundation Annual Lecture, Christchurch, October 1981 (by invitation). Blood lipids and heart disease. E.D. Janus.
10. M.R. Wardell*, P.A. Suckling and E.D. Janus. Genetic variation in human apolipoprotein E. N.Z.A.C.B. Conference, Christchurch, 1981. This paper won the Abbott Award for the best paper presented at the conference.

A.A.C.B. Conference, Melbourne, November, 1981 - the same paper presented by M.R. Wardell* by invitation.
11. 6th International Symposium on Atherosclerosis, Berlin, June 1982. VLDL Apo E polymorphism. E.D. Janus*, L.M. Sinclair and M.R. Wardell.

The same paper was presented at the University of Munster, West Germany and at Erasmus University, Rotterdam The Netherlands (by invitation).

12. Human Genetics Society of Australasia Annual Conference, Wellington, N.Z., October 1982.
Reflux nephropathy - a mendelian dominant gene?
E.D. Janus*, R.R. Bailey, K.L. Lynne and G.D. Abbott.
13. Symposium on Reflux nephropathy, Santa Barbara, U.S.A., October 1982. Familial and genetic data in reflux nephropathy.
R.R. Bailey*, E.D. Janus, K. McLoughlin, K.L. Lynn and G.D. Abbott.
14. South Pacific Science Congress, Dunedin, February 1983. Insulin dependant diabetes mellitus.
E.D. Janus (by invitation).
15. Christchurch Medical Research Society, April 1983. Lipoprotein metabolism in Type III hyperlipoproteinaemia.
E.D. Janus*, S. Grant, L.M.T. Sinclair and J. Bates.
16. Australasian Atherosclerosis Society, 10th Annual Scientific Meeting, Sydney, May 1983.
Lipoprotein metabolism in Type III hyperlipoproteinaemia.
E.D. Janus*, S. Grant, L.M.T. Sinclair and J. Bates.
17. Christchurch Medical Research Society, July 1983. The genetic basis of vesico ureteric reflux and reflux nephropathy.
E.D. Janus*, R.R. Bailey, C.J. Chapman, G.D. Abbott, K.L. Lynn.
18. Sixth International Symposium of Paediatric Nephrology, Hanover, August, 1983. Familial Reflux Nephropathy.
R.R. Bailey*, E.D. Janus, K.L. Lynn, C. Chapman, and G.D. Abbott.
19. 56th Scientific Sessions, American Heart Association, Anaheim, California, November 1983.
Lipoprotein metabolism in Type III hyperlipoproteinaemia.
E.D. Janus*, S. Grant, J. Bates, and R. Wootton.
20. The Royal Australasian College of Physicians Annual Clinical and Scientific Meeting, Dunedin, November 1983. Type III Hyperlipoproteinaemia in Identical Twins.
E.R. Nye*, W.H.F. Sutherland and E.D. Janus.
21. Christchurch Medical Research Society, April 1984. Smoking, Lung function and alpha-1-antitrypsin deficiency. A follow up study.
E.D. Janus* and N.T. Phillips
22. Christchurch Medical Research Society, April 1984.
The effect of phenobarbital on circulating levels of alpha-1-antitrypsin.
I. Bathurst*, M. Lorier, J. Sharman, E.D. Janus and R.W. Carrell.
23. Plasma Proteins : Synthesis and Secretion. ABS-NZBS Meeting, Hammer Springs April 1984.
Isolation and Heterogeneity of Apolipoprotein E.
M.R. Wardell*, E.D. Janus, S.O. Brennan and R.W. Carrell.
24. Australian Atherosclerosis Society, 11th Annual Scientific Meeting, Melbourne, May 1984.
Effects of clofibrate in the treatment of homozygous and heterozygous Type III hyperlipoproteinaemia.

E.D. Janus*, S. Grant and M.R. Wardell.

25. DNA and Medical Practice. Wellington Postgraduate Society Course, Wellington, May 1984. Genetic Variation in Heart disease. E.D. Janus.
26. Human Genetics Society of Australasia N.Z. Branch Annual Scientific Meeting, Wellington May 1984. Smoking, lung function and alpha-1-antitrypsin deficiency. E.D. Janus*, and N.T. Phillips.
27. The New Zealand Dietetic Association, Annual Conference, Christchurch, August 1984. Preventing Ischaemic Heart Disease. E.D. Janus.
28. The Royal New Zealand College of General Practitioners, Canterbury Branch, August 1984. Recent advances in the diagnosis and management of hyperlipidaemia. E.D. Janus.
29. XV World Congress on Disease of the Chest, Sydney, Australia, August 1985. Smoking, lung function and alpha-1-antitrypsin deficiency. E.D. Janus*, N.T. Phillips and R.W. Carrell.
30. 1 Antitrypsin - Molecules and Medicine, Workshop, St.John's College, Cambridge, England, September 1985. Emphysema in alpha-1-antitrypsin deficiency. E.D. Janus (by invitation).
31. 7th International Symposium on Atherosclerosis, Melbourne, Australia, October 1985.
 - (i) Apolipoprotein B metabolism in type III hyperlipoproteinaemia and in hypercholesterolaemic E2/2 subjects. E.D. Janus*, S.J. Grant, L.M.T. Sinclair and R. Wootton.
 - (ii) A new molecular abnormality of apolipoprotein E in type III hyperlipoproteinaemia. M.R. Wardell*, S.O. Brennan, R. Fraser, R.W. Carrell and E.D. Janus.
 - (iii) Post heparin lipase activities in treated and untreated type III hyperlipoproteinaemia and hypocholesterolaemic subjects with apo E2/2 phenotype. W.H.F. Sutherland*, E.D. Janus, E.R. Nye and S.J. Grant.
32. AACB 23rd Annual Conference, Melbourne, Australia, October 1985. Fredrickson's Classification in 1985. E.D. Janus (by invitation).
33. Second International Symposium on Pulmonary Emphysema and Proteolysis, Pasadena, California, U.S.A. January 1986. Smoking, alpha-1-antitrypsin deficiency and emphysema. E.D. Janus (by invitation).
34. XII Congress International Society for Heart Research, "Receptors, metabolism and the myocardium", Melbourne, Australia, February 1986. Receptor binding defects in familial hyperlipoproteinaemias associated with premature ischaemic heart disease. E.D. Janus*, S. Grant, M. Wardell and S. Brennan. (Awarded prize for best Australian Poster).
35. National Heart Foundation of Australia Heart Week Seminar, "It's high time to lower cholesterol", Melbourne, April 1986. Detection and Management of hyperlipidaemia. E.D. Janus.

36. 30th Annual Conference of Australian Biochemistry Society, Melbourne, Australia, May 1986. Type III hyperlipoproteinaemia - a genetic disorder of apolipoprotein E. E.D. Janus*, S. Grant, M. Wardell and S. Brennan (by invitation).
37. VMPPF Country Education Programme, Goulbourn Valley Base Hospital, Shepparton, July 1986. Hyperlipidaemia: diagnosis and management. E.D. Janus.
38. Postgraduate course : Adult Cardiology and Cardiac Surgery. The University of Melbourne, August 1986. Diet, lipids and coronary atherosclerosis. E.D. Janus.
39. Society of Hospital Pharmacists of Australia (Victorian State Branch), Melbourne 1986. Elevated serum lipid levels - their significance and their treatment. E.D. Janus.
40. Australian Atherosclerosis Society, Annual Scientific Meeting, Melbourne, October 1986. Plasma lipids and lipoproteins in patients undergoing cardiac surgery. T. Billington*, G.F. Carter, J. Lau, and E.D. Janus.
41. Joint Meeting Queensland Divisions of the Australian Nutrition Foundation, Dietitians Association of Australia, ANZSERCH and Nutrition Society of Australia. Brisbane, October 1986. Diet and Heart Disease - Prevention and treatment. E.D. Janus.
42. Joint Australian Nutrition Foundation - Queensland Division, Family Medicine Programme: Nutrition Programme for Medical Practitioners, Brisbane, October 1986. Symposium of Dietary Consideration in Heart Disease and Diabetes. E.D. Janus, J. Walker, S. Capra (participants).
43. VMPPF Country Education Programme, Colac Hospital, Colac, November 1986. Diet for hyperlipidaemia. E.D. Janus.
44. Clinical Society Meeting, Mitcham and District Private Hospital, Mitcham, February 1987. Detection and Treatment of Hyperlipidaemia. E.D. Janus.
45. VMPPF Country Education Programme 1987
Hyperlipidaemia Seminars. E.D. Janus.

Mildura Base Hospital - February 1987
East Gippsland Hospital - Bairnsdale - May 1987
Warnambool District Base Hospital - May 1987
Central Gippsland Hospital - Traralgon - August 1987
46. Royal Australian College of General Practitioners - General Practice Group Seminars. "Diet, Heart Disease and the Management of Hyperlipidaemia". E.D. Janus.
47. William Angliss Hospital, Ferntree Gully - May 1987
Waringal Private Hospital, Heidelberg - July 1987
St. George's Hospital, Kew - August 1987
48. Royal Australian College of General Practitioners - Family Medicine Programme. "Preventive skills in General Practice" - Melbourne, June 1987. E.D. Janus.

49. General Practitioner Education Series in conjunction with Astra Pharmaceuticals. "Time to treat cholesterol seriously in General Practice". E.D. Janus.
- | | | |
|----------------------------|---|----------------|
| AMA Peninsula Subdivision, | - | May 1987 |
| Frankston | | |
| Wangaratta | - | June 1987 |
| AMA Subdivision Meeting, | - | July 1987 |
| Collingwood | | |
| Shepparton | - | August 1987 |
| Albury (NSW) | - | August 1987 |
| South Melbourne | - | August 1987 |
| Ballarat | - | September 1987 |
| Hobart (Tas) | - | September 1987 |
| Bendigo | - | September 1987 |
50. Royal Childrens' Hospital, Melbourne, Cardiology Department Seminar. "Diet, Heart Disease and Hyperlipidaemia" - July 1987.
51. Royal Melbourne Hospital, Nephrology Department Seminar. "Hyperlipidaemia in the Nephrotic Syndrome and the Hyperlipidaemia associated with Chronic Renal Failure", August 1987.
52. Royal Australasian College of Pathologists Annual Scientific Meeting, Adelaide, October 1987.
- Lipids and lipoprotein lipids in patients undergoing coronary artery grafting.
T. Billington, H.C. Sinclair and E.D. Janus*.
- Comparison of total, corrected and dialysable calcium with free calcium in a hospital based population.
D.S. Kleinman*, R. Norris, G. Carter, C. Baker and E.D. Janus.
53. Australian Association of Clinical Biochemists Annual Scientific Meeting, Adelaide, October 1987.
- Lipids and lipoprotein lipids in patients undergoing coronary artery grafting.
T. Billington*, H.C. Sinclair and E.D. Janus.
- Comparison of total corrected and dialysable calcium with free calcium in a hospital based population.
D.S. Kleinman, R. Norris, G. Carter, C. Baker* and E.D. Janus.
- Monoclonal and oligoclonal bands detected in a general hospital population over a two year period.
P. Di Sciascio*, D.M. Shaw and E.D. Janus.
54. Australian Atherosclerosis Society. Annual Scientific Meeting. Bateman's Bay, February 1988.
Lipoproteins and apoproteins in coronary heart surgery patients. T. Billington*, H.C. Sinclair, J. Steele and E.D. Janus.
55. VMPF Country Education Programme, 1988.
Hyperlipidaemia Seminar, E.D. Janus.
- Hamilton Base Hospital - April 1988.

Bendigo and Northern District Base Hospital - August 1988.

56. 8th International Symposium on Atherosclerosis, Rome, Italy, October 1988
- i) Human apolipoprotein E: HPLC separation and preparation of tryptic peptides for primary sequence studies in type III.
T. Billington* and E.D. Janus.
 - ii) Lipoproteins and apoproteins in coronary artery surgery patients.
E.D. Janus*, T. Billington, H.C. Sinclair and J. Steele.
 - iii) Lipids, lipoproteins and apolipoproteins A1 and B in chronic ambulatory peritoneal dialysis and haemodialysis patients.
J. Steele*, T. Billington, J. Moran, M.J. Lysaght and E.D. Janus.
57. Australian Association of Clinical Biochemists Annual Scientific Meeting, Sydney, October, 1988.
"An integrated computer controlled laboratory analysis and reporting system incorporating the Olympus AU5031.
G. Carter*, P. Pretty, M. Mohr and E.D. Janus.
58. ACPHER Physical Education Conference, Monash University, December, 1988. "You may think you're fit but still have a high cholesterol"
E.D. Janus (by invitation).
59. National Assessment Officers Conference Ballarat, October 1988.
The significance of blood lipids in the development of cardiovascular and circulatory problems.
E.D. Janus (by invitation).
60. VMPF Country Education Programme 1989
Management of Hyperlipidaemia - New aspects
- Swan Hill - February 1989
- Horsham - June 1989
61. RACGP Seminar
Ferntree Gully Hospital, July 1989
Management of Hyperlipidaemias - New aspects
62. Australian Atherosclerosis Society, 15th Annual Scientific Meeting, McLaren Vale, South Australia, May 1989.
- i) Apolipoprotein (a) in coronary artery surgery patients E.D. Janus*, J. Steele and T. Billington.
 - ii) Lipids, lipoproteins and apolipoproteins A1 and B and their dialysate losses in chronic renal failure patients treated with continuous ambulatory peritoneal dialysis.
J. Steele*, T. Billington and E.D. Janus.
 - iii) HPLC separation of tryptic peptides of apoprotein E variants.
T. Billington* and E.D. Janus.

63. Association of Clinical Biochemists (UK) Annual Scientific Meeting, Birmingham, May 1989.
A bidirectional computer controlled laboratory analysis and reporting system incorporating the Olympus AU5031 Random Access Analyser and Hewlett-Packard 1000 computer.
M. Mohr*, P. Pretty, G. Carter and E.D. Janus.
64. American Association for Clinical Chemistry National Meeting, Atlanta, Georgia, July, 1989.
An integrated computer controlled laboratory analysis and reporting system incorporating the Olympus AU5031.
G. Carter*, P. Pretty, M. Mohr and E.D. Janus.
65. Royal College of Pathologists of Australasia, 34th Annual Scientific Meeting, Hong Kong, September 1989.
Apolipoprotein E genotypes and lipoprotein disorders.
E.D. Janus (by invitation).
66. National Heart Foundation of Australia. Dietitians Update Meeting, Melbourne, October, 1989.
Why lower plasma lipids? The Role of Current and New Drugs.
E.D. Janus.
67. 4th Epworth Cardiology Seminar, Ballarat, November, 1989.
Development in the Management of Cardiovascular Risk Factors - lipids.
E.D. Janus (by invitation).
68. ACHPER Physical Education Conference, Monash University, December 1989.
"You may think you're fit but still have a high cholesterol:
E.D. Janus (by invitation).
69. VMPF Country Education Programme, 1990
La Trobe Valley Hospital, Moe, February 1990 - Hyperlipidaemia management.
E.D. Janus.
70. RCPA/AACB Chemical Pathology Course, February 1990, Melbourne.
Lipids - their clinical significance.
E.D. Janus.
71. Healesville General Practitioners, February 1990, hyperlipidaemia and its treatment.
E.D. Janus.
72. Melbourne University Department of Biochemistry B.Sc Hons Seminar, March 1990.
Structure and Function of apolipoprotein E.
E.D. Janus (by invitation).
73. IDP visitor to Hospital Universiti Sains Malaysia (USM), Kota Bharu and invited speaker at the University of Malaysia and at the National University of Kuala Lumpur.
- (i) Intensive Course in Endocrinology, Hospital Universiti Sains Malaysia, Kota Baru, March 1990.
A review of primary hyperlipidaemia and hyperlipidaemia in diabetes mellitus.
E.D. Janus.
- (ii) University Hospital, University of Malaysia, Kuala Lumpur, March 1990.
Lipid Disorders - the advancing edges.

E.D. Janus (invited speaker, Grand rounds).

(iii) The Malaysian Society of Pathologists and the Department of Pathology, Universiti Kebangsaan, Kuala Lumpur, Malaysia, March 1990.
Primary hyperlipidaemia and hyperlipidaemia in diabetes mellitus.
E.D. Janus (by invitation).

(iv) Hospital Universiti Sains Malaysia, Kota Bharu, March 1990.
Familial Hypercholesterolaemia.
E.D. Janus (invited speaker) in Grand Rounds Seminar "Hypercholesterolaemia in Kelantan".

74. Melbourne University, Department of Biochemistry lecture to Medical and Dental Students, April 1990/91/92.

Genetic abnormalities of lipoprotein structure and function.

E.D. Janus (by invitation).

75. Triglycerides: The role in diabetes and atherosclerosis.
Vienna, May 1990.

(i) Lipid levels in an Australian non insulin dependent diabetic (NIDDM) population are comparable to those in a non diabetic population undergoing coronary artery grafting.

E.D. Janus*, A.J. Jenkins, J.D. Best, T. Billington.

(ii) Increased apo (a) levels in type I diabetic patients with albuminuria.

A.J. Jenkins*, J.S. Steele, E.D. Janus, J.D. Best.

76. VMPPF Country Education Programme, 1990.

"What's new in plasma lipids", E.D. Janus.

Central Gippsland Hospital, Traralgon, June 1990.

Goulbourn Valley Base Hospital, Shepparton, Sept. 1990.

Gippsland Base Hospital, Sale, October 1990.

77. Clinical Meeting, Dandenong & District Hospital, Dandenong, August 1990.

New aspects of the management of Hyperlipidaemia.

E.D. Janus.

78. AMA Divisional Meeting, Collingwood, September 1990.

Hyperlipidaemia and Heart Disease. High risk and population strategies.

E.D. Janus.

79. Australian Diabetes Society, Annual Scientific Meeting, Perth - September 1990.

Increased apo(a) levels in type I diabetic patients with albuminuria.

A.J. Jenkins*, J.S. Steele, E.D. Janus, J.D. Best.

80. Australian Atherosclerosis Society, 16th Annual Scientific Meeting, Leura, September 1990.

(i) Strategies for prevention and treatment of heart disease.

E.D. Janus.

- (ii) Lipids in Diabetes Mellitus.
A.J. Jenkins^{*}, E.D. Janus, J.D. Best, J.S. Steele and T. Billington.
 - (iii) Apolipoprotein CII deficiency: Characterisation using a molecular biological approach.
J.S. Steele, T. Billington, M. Mansur and E.D. Janus^{*}.
 - (iv) Apolipoprotein E (apo E) variants: DNA characterization by genotyping.
T. Billington^{*}, J.S. Steele and E.D. Janus.
81. Royal Australian College of General Practitioners.
Current Cardiac Controversies Seminar, November, 1990.
Hyperlipidaemia - current concepts in management.
E.D. Janus.
82. Pharmaceutical Society of Australia. Victorian Branch. Continuing Education programme,
March, 1991.
Drug treatment of hyperlipidaemia.
E.D. Janus.
83. VMPF Country Education Programme 1991.
"Treatment of raised lipids". E.D. Janus

La Trobe Valley Hospital, Moe, April 1991.
84. Annual Scientific Meeting, Thoracic Society of Australia and New Zealand, Lorne, Vic, April
1991.
- (i) Pi Null Bellingham and early onset of emphysema.
L. Cook^{*}, E.D. Janus, B. Biegler and E. Tai.
 - (ii) Alpha-1-antitrypsin replacement therapy - an early Australian experience.
J. Burdon^{*}, L. Cook, E. Janus and S. Watts.
85. 14th International Diabetes Federation Congress, Washington D.C. June 1991.
Increased apo(a) levels in IDDM patients with microalbuminuria.
A.J. Jenkins^{*}, J.S. Steele, E.D. Janus, J.D. Best.
86. Macrovascular complications of Diabetes Mellitus (14th IDDF Congress satellite program),
Charleston, South Carolina, June 1991.
Plasma apo(a) is increased in NIDDM patients with microalbuminuria.
A.J. Jenkins^{*}, J.S. Steele, E.D. Janus, J.D. Best.
87. Australian Atherosclerosis Society, 17th Annual Scientific Meeting, Perth, August 1991.
- (i) Increased plasma apo(a) levels in diabetic patients with macrovascular disease,
microalbuminuria and albuminuria.
A.J. Jenkins, J.S. Steele, E.D. Janus^{*}, J.D. Santamaria and J.D. Best.
 - (ii) Apolipoprotein E: phenotyping and genotyping.
T. Billington^{*} and E.D. Janus.
 - (iii) Fibrinogen, factor VII activity and plasminogen activator activity inhibitor abnormalities in
insulin dependent diabetes mellitus patients with albuminuria.

A.J. Jenkins, P. Lee, C. Paton, E.D. Janus* and J.D. Best.

88. Royal College of Pathologists of Australasia, 36th Annual Scientific Meeting, Melbourne, October, 1991.
- (i) Apolipoprotein (a) and atherogenesis.
E.D. Janus* (by invitation).
 - (ii) The effect of low plasma protein on sodium levels.
Samuel X.B. Zheng*, Ann Read and E.D. Janus.
89. 9th International Atherosclerosis Symposium, Chicago, USA, October, 1991.
- (i) A splice site mutation in the apo CII gene in a kindred with partial apo CII deficiency (apo CII Kota Bharu).
J.S. Steele*, M. Mansur, T. Billington and E.D. Janus.
 - (ii) Increased plasma apo(a) in patients with type II diabetes and microalbuminuria.
A.J. Jenkins, J.S. Steele, E.D. Janus*, J.D. Santamaria and J.D. Best.
90. Australian Association of Clinical Biochemists, Perth, October, 1991.
- (i) Alpha-1-antitrypsin replacement therapy - an early Australian Experience.
J. Burdon, L. Cook*, E. Janus, S. Watts and P. Holmes.
 - (ii) Pi Null Bellingham and early onset of emphysema.
L. Cook*, E.D. Janus, B. Biegler and E. Tai.
Awarded AACB Pacific Diagnostics Prize.
 - (iii) Improved alkaline phosphatase reagent stability using an evacuated reagent container system.
G. Carter*, G. Grieve and E.D. Janus.
 - (iv) Evaluation of the trace surfactant total bilirubin reagent on the Olympus 5031.
G. Carter*, C. Parslow and E.D. Janus.
 - (v) Increased plasma apo(a) levels in diabetic patients with macrovascular disease, microalbuminuria and albuminuria.
A.J. Jenkins, J.S. Steele*, E.D. Janus and J.D. Best.
91. St. John of God Postgraduate Foundation Symposium "Hyperlipidaemia and vascular disease. Where are we now?"
Ballarat, October, 1991.
- Atheroma and the relevance of serum lipid levels.
E.D. Janus (by invitation).
- Drug therapy and hyperlipidaemia in 1991.
E.D. Janus (by invitation).
92. St. Vincent's Inaugural Research Week, October, 1991.
15 posters presented by members of Department of Chemical Pathology.

93. National Heart Foundation of Australia (Victorian Division) ""Diet and Heart Disease". Dietitians update seminar, Melbourne, November 1991.
Coronary Heart Disease - epidemiology, regression and update on drug treatment of hyperlipidaemia.
E.D. Janus (by invitation)
94. Universita di Milano, Istituto di Scienze Farmacologiche, Milan, Italy, December, 1991.
A splice site mutation in the apo CII gene in a kindred with partial apo CII deficiency (Apo CII Kota Bharu).
J.S. Steele, E.D. Janus^{*}, M. Mansur and S.S. Fojo.
95. Austrian Biochemical Society, Institute of Medical Biochemistry, University of Graz, Austria, December, 1991.
A splice site mutation of apo CII.
J.S. Steele, E.D. Janus^{*}, M. Mansur and S.S. Fojo.
96. St Bartholomew's Hospital, London UK, Department of Human Genetics and Metabolism, January, 1992.
- (i) A splice site mutation in apo CII (apo CII Kota Bharu).
J.S. Steele, E.D. Janus^{*}, M. Mansur and S.S. Fojo.
- (ii) Declines in cardiovascular mortality in Australia, National Risk Factor Prevalence Studies, the Food Approval Programme and strategies for prevention.
E.D. Janus.
97. University of Newcastle upon Tyne, UK, Royal Victoria Infirmary, Newcastle, January, 1992.
Declines in cardiovascular mortality in Australia.
E.D. Janus.
98. University of Glasgow, Royal Infirmary, Glasgow, Scotland. January 1992.
Apolipoprotein (a) and coagulation factors in diabetes mellitus.
E.D. Janus^{*}, A.J. Jenkins, J.D. Best, J.S. Steele, J.D. Santamaria, P. Lee and C. Paton.
99. Centre for Genetics of Cardiovascular Disorders, Department of Medicine, University College and Middlesex School of Medicine, Rayne Institute, London, UK. January 1992.
Progress in fats and lipids down under.
(Apo CII deficiency, coagulation defects in diabetes mellitus and changes in cardiovascular disease mortality in Australia).
E.D. Janus.
100. TNO Institute of Ageing and Vascular Research.
The Netherlands, January, 1992.
- (i) A splice site mutation in apo CII (apo CII Kota Bharu).
J.S. Steele, E.D. Janus^{*}, M. Mansur and S.S. Fojo.
- (ii) Increased plasma apo(a) levels in diabetic patients with macrovascular disease, microalbuminuria and albuminuria.
A.J. Jenkins, J.S. Steele, E.D. Janus^{*}, M. Mansur and S.S. Fojo.

(iii) Fibrinogen, factor VII activity and plasminogen activator inhibitor abnormalities in patients with IDDM and microalbuminuria.

A.J. Jenkins, P. Lee, C. Paton, E.D. Janus* and J.D. Best.

101. Academisch Ziekenhuis St.Radboud, Katholieke Universiteit Nymegen, The Netherlands, January, 1992.
Apo(a) in diabetic patients.
E.D. Janus.
102. Department of Human Nutrition, Agricultural University, Wageningen, The Netherlands, January 1992.
Declines in cardiovascular mortality in Australia, National Risk Factor Prevalence Studies, the Food Approval Programme and Strategies for Prevention.
E.D. Janus.
103. Singapore Cardiac Society Symposium: The Management of Hypercholesterolaemia, Singapore, February 1992.
New approaches in the management of hypercholesterolaemia: The Australian Experience.
E.D. Janus (by invitation).
104. General Hospital, Kota Bharu, Malaysia, February 1992.
New approaches in the management of hypercholesterolaemia.
E.D. Janus (by invitation).
105. Combined Faculty Clinical Meeting, School of Medicine, Universiti Sains Malaysia, Kota Bharu, Malaysia, February 1992.
New aspects in the diagnosis and management of hyperlipidaemia.
E.D. Janus (by invitation).
106. Malaysian Endocrine and Metabolic Society.
Satellite Symposium: Cardiovascular Risk Management.
Kuala Lumpur, Malaysia, February 1992.
New approaches in the management of hypercholesterolaemia: The Australian Experience.
E.D. Janus (by invitation).
107. Combined Clinical Faculty Meeting, Faculty of Medicine, University Hospital, Universiti Malaya, Kuala Lumpur, Malaysia, February 1992.
Abnormalities of Lipid Metabolism.
E.D. Janus (by invitation).
108. AMA Divisional Meeting, Collingwood, March 1992.
"New Aspects of hyperlipidaemia" E.D. Janus.
109. Thoracic Society of Australia and New Zealand Annual Scientific Meeting. Canberra, ACT, Mar 30th - Apr 2nd, 1992.
Alpha-1-antitrypsin phenotype F - High risk for development of emphysema.
L. Cook, J. Burdon*, E.D. Janus & S. Watts.
110. VMPF Country Education Programme, 1992. Wangaratta. April 1992.
"New Aspects of hyperlipidaemia"
E.D. Janus.
111. Australian, South East Asia and New Zealand Lipid Forum Terrigal NSW, June 1992.

Management of hyperlipidaemia in women and the elderly.
E.D. Janus.

112. AACB (Victorian Branch), Melbourne, July 1992.
Lipids - the challenges of the nineties.
E.D. Janus.
113. AIMS (Gippsland Division), Melbourne, July 1992.
Lipid Disorders - future challenges.
E.D. Janus.
114. Diabetic Dyslipidaemia - Developments and directions, Melbourne and Sydney, August, 1992
The prevalence and detection of lipid disorders in diabetes.
E.D. Janus.
115. European Respiratory Society Annual Congress - Vienna 1992. Aug 29 - Sept 3, Austria Center.
Alpha-1-antitrypsin phenotype F - High risk for development of emphysema.
L. Cook, J. Burdon*, E.D. Janus & S. Watts.
116. 1992 R.C.P.A Conference - Cairns, September 30 1992.
Assessment of Chemical Pathology Screening in Femoral Neck Fracture Admissions.
K.A. Sikaris*, A. Read, C. Baker, L. Osborne & E.D. Janus.
117. Australian Association of Clinical Biochemists, Hobart, October, 1992.
- (i) A Non-Cyanide HPLC Method for Haemoglobin A_{1c}.
J. Varsos & E.D. Janus.
 - (ii) Apolipoprotein E Typing: The Complete Picture?
J. Steele & E.D. Janus.
 - (iii) An Abnormal Association Constant for Alpha-1-antitrypsin Phenotype F -A Potential Factor in Emphysema in a Pi FZ Patient.
L. Cook, J. Burdon, E.D. Janus & S. Watts.
 - (iv) The Effect of Low Plasma Protein on Sodium Levels.
Samuel X.B. Zheng, Ann Read and E.D. Janus.

118. 12th Senri Seminar, International Conference on Lipoproteins, thrombosis and atherosclerosis. Susonno, Shizuoka, Japan, October 1992.
Apolipoprotein(a) and arterial disease.
E.D. Janus (by invitation).
119. Hong Kong Society of Clinical Chemists Workshop, Hong Kong, February 1993.
"Beyond cholesterol".
E.D. Janus.
120. Symposium on Disease states: Diagnosis and monitoring through protein/drug measurement, Hong Kong, February, 1993.
Microalbuminuria.
E.D. Janus.
121. Queen Elizabeth Hospital, Hong Kong, May 1993.
Hyperlipidaemia, its investigation and management.
E.D. Janus.
122. Hong Kong Society of Clinical Chemists Workshop on Laboratory Computerisation, Hong Kong, May 1993.
The Australian experience.
E.D. Janus.
123. The Hong Kong Pathology Society, Transplantation Symposium, Hong Kong, June, 1993.
An update on biochemical aspects of transplantation.
E.D. Janus.
124. Tuen Mun Hospital, Hong Kong, June 1993.
Clinical and Laboratory Management of Hyperlipidaemia.
E.D. Janus.
125. ASEANZ LIPID FORUM, Current challenges in the Diagnosis and Management of Lipid and Lipoprotein Disorders Singapore, July, 1993.

Guidelines in the diagnosis and management of Hyperlipidaemia.
E.D. Janus.

Update on Lipoprotein (a) and its clinical relevance.
E.D. Janus.
126. Princess Margaret Hospital, Hong Kong, September, 1993.
Treating hyperlipidaemia - why and when?
E.D. Janus.
127. Annual Scientific Meeting, Society for the Study of Endocrinology, Metabolism and Reproduction, Hong Kong, October 1993.
Serum apolipoprotein (a) correlates with growth hormone levels in Chinese patients with acromegaly.
R.W.C. Pang*, K.S.L. Lam, E.D. Janus, A.W.C. Kung, C.C.L. Wong (Awarded best paper prize).
128. University Health Service, University of Hong Kong, October, 1993.
The management of hyperlipidaemia.
E.D. Janus.

129. Institute of Molecular Biology (IMB) & Department of Medicine (University of Hong Kong) Retreat, November, 1993.
Genetic factors in coronary heart disease - applications of molecular biology.
130. XV International Congress of Clinical Chemistry, Melbourne, Australia, November, 1993
- (i) Apolipoprotein E phenotyping and genotyping.
E.D. Janus (by invitation).
 - (ii) Clinical usefulness of routine typing of proteinuria.
J. Ficarra*, M. Shaw, R. Boyd-Gerny, A. Read & E.D. Janus.
 - (iii) # The use of 10% thymol as a preservative for urinary albumin measurement on the Beckman Array System.
W.C. Pang*, S.W. Ng & E.D. Janus.
 - (iv) Plasma lipids and lipoproteins in angioplasty patients.
G. Hale, R. Galluzzo, T. Billington, K. Sikaris*, E.D. Janus, P. Fox, G. Leitl, M. Rowe.
 - (v) An abnormal association constant for alpha-1-antitrypsin phenotype F - a potential factor in emphysema in a PiFZ patient.
L. Cook*, J. Burdon, E. Janus, S. Watts.
- # See below.
131. International Symposium on Clinical Lipidology - Satellite Meeting of XV International Congress of Clinical Chemistry - Cairns, Australia, November, 1993.
- (i) Apolipoprotein (a), coronary heart disease and diabetes.
E.D. Janus.
 - (ii) Serum apolipoprotein (a) correlates with growth hormone levels in patients with acromegaly.
K.S.L. Lam, R.W.C. Pang*, E.D. Janus, A.W.C. Kung and C.C.L. Wong.
132. San Diego Conference on Nucleic Acids: Beyond DNA probes. San Diego, USA, November, 1993.

Fibrinogen and Factor VII variation in the Hong Kong Chinese population.
O.C.K. Ma*, C. Bourke, E.D. Janus, L.C. Chan & K.S.L. Lam.
133. Asian Pacific Congress on Lipid Risk Factor Control, Hong Kong, January 1994.
- (i) Smoking and cardiovascular disease - known and potential mechanisms.
E.D. Janus.
 - (ii) # Growth hormone therapy increases apolipoprotein (a) in β -Thalassaemia major children with short stature without GH deficiency.
S.C.F. Tam*, R.W.C. Pang, E.D. Janus, E. Kwan, L.C.K. Low.
 - (iii) # Levels of plasma apolipoprotein (a) in a Hong Kong Chinese population.
R.W.C. Pang*, E.D. Janus and K.S.L. Lam.

- (iv) # ** Fibrinogen and factor VII variation in the Hong Kong Chinese population.
E.D. Janus*, O.C.K. Ma, C. Bourke, L.C. Chan and K.S.L. Lam.
- (v) # Identification of (Pro₆₆₄ → Leu) mutation in low density lipoprotein receptor gene in Chinese patients with familial hypercholesterolaemia.
K.K. Wong, G. Srivastava, E.D. Janus, M.S. Wat, K.S.L. Lam and F.C.S. Ho.
- # Also presented at Hong Kong Society of Clinical Chemistry Annual Scientific Meeting, Hong Kong, January 1994.
- ** Best poster presentation award.

134. Development of Clinical Sciences in Hong Kong - Association of Scientific Officers (Medical) Seminar, March 1994.
Future Directions in Chemical Pathology.
E.D. Janus (by invitation).
135. 1st Medical Congress - CEBU Medical Society, Cebu, Philippines, April 1994.
Lipid disorders and coronary heart disease. The past, present and future perspectives.
E.D. Janus (by invitation).
136. ASEANZ Lipid Forum. Management strategies. Confronting the risk for coronary heart disease. Taoyuan, Taiwan, June 1994.
- (i) How the laboratory assists in the diagnosis of lipid disorders.
(Workshop: E. Stein, E.D. Janus and K.K. Lin)
 - (ii) How to establish therapeutic targets for lipid management in Asia.
(Workshop: A. Keech, E.D. Janus & Y.O. Ding)
- Conference Consultant & Co chairman of Plenary Workshop Summary Session - E.D. Janus.
137. Multiple Risk Factors in Cardiovascular Disease. Vascular and Organ Protection, Florence, Italy, July 1994.
Genetic variation of fibrinogen in Hong Kong Chinese Diabetic Patients.
E.D. Janus*, O.C.K. Ma, C. Bourke, L.C. Chan and K.S.L. Lam.
138. 21st World Congress of Medical Technology, Hong Kong, July 1994.
- (i) Current challenges in Coronary Heart Disease - the role of Laboratory Medicine.
E.D. Janus (by invitation).
 - (ii) Sensitivity and specificity of three laboratory methods for the detection of microalbuminuria in a population of diabetic outpatients.
R.W.C. Pang*, T.M.Y. So, K.S.L. Lam and E.D. Janus.
139. Symposia on Lipids and Coronary Artery Disease. The Society of Lipids and Atherosclerosis (Republic of China) and International Lipid Information Bureau (ILIB) Taiwan. Taichung & Kaohsiung, August 1994.
Lipid abnormalities in Cardiovascular Disease - New aspects.
E.D. Janus (by invitation).
140. Korean Society of Lipidology, Seoul, Korea, September 1994.
Cardiovascular and risk factor epidemiology in Hong Kong including proposed Hong Kong Guidelines for Management of Lipid Disorders.

E.D. Janus (by invitation).

141. Xth International Symposium on Atherosclerosis, Montreal, Canada, October 1994.
Genetic variation of Factor VII in Hong Kong Chinese diabetic patients.
E.D. Janus*, O.C.K. Ma, C. Bourke, L.C. Chan and K.S.L. Lam.
142. Hospital Authority Convention, Hong Kong, January, 1995
- (i) Utilisation of blood gas estimations at Queen Mary Hospital.
E.D. Janus*, S.S.S. Chan and J.S.K. Lee.
 - (ii) Laboratory courier system improvements in Queen Mary Hospital.
E.D. Janus*, M. Au and B.M.W. Fong.
 - (iii) Feasibility study of installation of pneumatic tube system.
J.T. Yien*, C. Leung, H.M. Shih, Y.W. Wan, V. Wong, R. Wong and E.D. Janus.
 - (iv) Phlebotomy nurse pilot study.
C.K. Chan*, E.D. Janus and Y.P. Liu.
143. Annual Scientific Meeting, Hong Kong Society of Clinical Chemistry, Hong Kong, January, 1995.
- (i) Utilisation of blood gas measurements at Queen Mary Hospital.
E.D. Janus*, J.S.K. Lee and S.S.S. Chan.
 - (ii) Laboratory courier system improvements in Queen Mary Hospital.
E.D. Janus*, M. Au and B.M.W. Fong.
 - (iii) Genetic variation of fibrinogen in Hong Kong Chinese diabetic patients.
E.D. Janus*, O.C.K. Ma, C. Bourke, L.C. Chan and K.S.L. Lam.
 - (iv) Genetic variation of factor VII in Hong Kong Chinese diabetic patients.
E.D. Janus*, O.C.K. Ma, C. Bourke, L.C. Chan and K.S.L. Lam.
 - (v) Sensitivity and specificity of three laboratory methods for the detection of microalbuminuria in a population of diabetic outpatients.
R.W.C. Pang, *T.M.Y. So, K.S.L. Lam and E.D. Janus.
 - (vi) Cholesterol lowering therapy may retard the progression of diabetic nephropathy.
K.S.L. Lam, I.K.P. Cheng, R.W.C. Pang* and E.D. Janus.
144. Third Annual Scientific Congress, Hong Kong College of Cardiology in conjunction with Second Congress of International Chinese Heart Health Network, Hong Kong, March, 1995.
- Prevalence of ischaemic heart disease and associated risk factors in the active aged.
N.S. Lok, C.P. Lau* and E. Janus.
145. Annual Scientific Meeting, Thoracic Society of Australia and New Zealand, Hobart, Australia, March, 1995.
Decline in FEV_{1.0} in patients with Pi ZZ alpha-1-antitrypsin deficiency.
S. Brenton, V. Hocking, J. Burdon, L. Cook, K. Knight, E.D. Janus.
146. American Endocrine Society Meeting, Washington, USA, June, 1995. Increased cholesteryl ester transfer activity in non-insulin-dependents with and without microalbuminuria.

K.C.B. Tan*, K.S.L. Lam, M.S. Wat, R.W.C. Pang and E.D. Janus.

147. Universiti Sains Malaysia, Medical Faculty, Kota Bharu, Malaysia, June 1995.
Molecular Diagnosis in Lipid Disorders.
E.D. Janus (by invitation).
148. Malaysian Medical Association, Kota Bharu, Malaysia, June 1995.
Current trends in the Management of Hyperlipidaemia.
E.D. Janus (by invitation).
149. XIIIth International Congress of Nephrology, Madrid, Spain, July, 1995.
Comparability of gemfibrozil and simvastatin in the treatment of hyperlipidaemia in renal transplant recipients - a randomised prospective study.
I.K.P. Cheng*, P.W.C. Li, E.D. Janus, C.S.O. Tang, T.M. Chan and C.Y. Lo.
150. 4th Congress of the Asian Society of Transplantation, Seoul, Korea, August, 1995.
Comparative efficacy of gemfibrozil and simvastatin in the treatment of hyperlipidaemia in renal transplant recipients - a randomised prospective study.
I.K.P. Cheng, P.W.C. Li, E.D. Janus, C.S.O. Tang, T.M. Chan, C.Y. Lo.
151. Aga Khan University, Second National Symposium on Basic and Applied Research in Health Care and Social Development, Karachi, Pakistan, September, 1995.
Effect of cholesterol rich diet on platelet reactivity, arachadonic acid metabolism and lipoprotein activity in relation to atherosclerosis.
R.V. Simjee*, E.D. Janus, T.R. Boyde and S.A. Saccd.
152. Cardiology towards 2000 - Festschrift for retirement of Dr. G.S. Hale, St. Vincent's Hospital, Melbourne, Australia, October, 1995.
Hyperlipidaemia - coronary heart disease prevention - Implications from recent trials.
E.D. Janus (by invitation).
153. United Christian Hospital, Hong Kong, November, 1995.
Hyperlipidaemia - coronary heart disease prevention - Implications from recent trials.
E.D. Janus.
154. 7th South East Asian - Western Pacific Regional Meeting of Pharmacologists, Manila, Philippines, November, 1995:
- (i) Studies of apolipoprotein-B kinetics in hyperlipidaemic states.
E.D. Janus (by invitation).
 - (ii) Guidelines in the management of hyperlipidaemias.
E.D. Janus (by invitation).
 - (iii) Genetic polymorphisms of fibrinogen and factor VII - implications for cardiovascular disease.
E.D. Janus (by invitation).
155. ISFC (International Society and Federation of Cardiology) & Society of Lipids and Atherosclerosis (Republic of China) Seminar, Kaohsiung and Taipei, Taiwan, November, 1995.
- (i) Implications of recent lipid lowering trials (Kaohsiung).
E.D. Janus.

- (ii) Newer risk factors - fibrinogen, factor VII and apo(a) in Southern Chinese (Taipei).
E.D. Janus.
156. The Philippine College of Physicians (Central - Eastern Visayas Chapter) and The Philippine Heart Association (Cebu chapter), Cebu, Philippines, November, 1995.
Lipid lowering agents in secondary prevention of CHD.
E.D. Janus.
157. ISFC (International Society and Federation of Cardiology) & ACEP (Asian Cholesterol Education Programme) Symposium - A New Look at Coronary Risk Factors, Manila, Philippines, November, 1995.

Cardiovascular Risk Factors: Recent Hong Kong and Southern Chinese Studies.
E.D. Janus.
158. National Heart Association of Malaysia. Weekend Lipid Course, "Current and future challenges in the management of lipid and lipoprotein disorders", Subang Jaya, Malaysia, November, 1995.
- (i) Epidemiology of cardiovascular risk factors.
E.D. Janus.
 - (ii) Newer risk factors - Fibrinogen, factor VII and apo(a).
E.D. Janus.
 - (iii) The female patient with hyperlipidaemia.
E.D. Janus.
159. Harapan Kita (National Cardiac Centre), Jakarta, Indonesia, November, 1995.
- (i) Cardiovascular risk factor epidemiology - recent Hong Kong studies.
E.D. Janus.
 - (ii) Implications of recent lipid - lowering end point studies.
E.D. Janus.
160. Grantham Hospital, Hong Kong, November, 1995.
Hyperlipidaemia - Coronary Heart Disease Prevention - Implications of recent trials.
E.D. Janus.
161. Indian College of Physicians (Moradabad Branch), Moradabad, India, December, 1995.
Hyperlipidaemia and coronary artery disease prevention.
E.D. Janus.
162. 4th Annual Conference of The Indian Society of Hypertension, Delhi, India, December, 1995.
- (i) Cardiovascular disease epidemiology - recent Hong Kong studies.
E.D. Janus (Invited Guest Lecture).
 - (ii) Workshop on Indian Consensus on Prevention of Coronary Heart Disease.
E.D. Janus (Co-chairman).

163. Hong Kong Society of Clinical Chemistry, Hong Kong, December, 1995.
The clinical significance of plasma proteins.
E.D. Janus.
164. Hong Kong Society of Clinical Chemistry, Annual Scientific Meeting, Hong Kong, January, 1996.
- (i) Cardiovascular Disease in Hong Kong - Insights from Clinical Biochemistry.
E.D. Janus (invited Plenary Lecture).
 - (ii) Apolipoprotein(a) genomic DNA size polymorphism in Southern Chinese.
R.W.C. Pang*, E.D. Janus, H.G. Kraft and G. Utermann.
165. Progressive and Integrated Medical Education Symposium for Philippine General Practitioners, Hong Kong, January, 1996.
Management of dyslipidaemia.
E.D. Janus (by invitation).
166. The Hong Kong Society for Rehabilitation Certificate Course in Coronary Artery Disease and Cardiac Rehabilitation 96, Hong Kong, February, 1996.
Lipid disorders.
E.D. Janus (by invitation).
167. 6th International Congress on Cardiovascular Pharmacotherapy, Sydney, Australia, February, 1996.
Diabetes and Atherosclerosis - Lipids and beyond.
E.D. Janus (by invitation).
168. Asian Pacific Congress on Vascular Disease Prevention, Singapore, March, 1996.
- (i) The Hong Kong Cardiovascular Risk Factor Prevalence Study.
E.D. Janus* and T.H. Lam for the Hong Kong Heart Health Steering Committee.
 - (ii) Apolipoprotein(a) genomic DNA size polymorphism in Southern Chinese.
R.C.W. Pang*, E.D. Janus, H.G. Kraft and G. Utermann.
 - (iii) LDL Subfractions in acromegaly.
K.C.B. Tan*, S.W.M. Shiu and E.D. Janus.
169. Hyperlipidaemia, coronary heart disease prevention, implications from recent trials. Yan Chai Hospital, March, 1996.
170. Hong Kong College of Cardiology, 4th Annual Scientific Congress, Symposium on Heart Disease, Hong Kong, April, 1996.

The Hong Kong Cardiovascular Risk Factor Prevalence Study.
E.D. Janus* and T.H. Lam for the project Steering Committee.
171. The Royal College of Physicians of Thailand. International Conference on Geriatric Medicine on the occasion of the Golden Jubilee Celebrations of his Majesty's Accession to the Throne, Pattaya, Thailand, April, 1996.

- (i) The prevalence of diabetes mellitus and thyroid diseases in the Hong Kong ambulant elderly population.
E.D. Janus* and A.W.C. Kung.
 - (ii) Lipid, lipoprotein and other biochemical parameters in the Hong Kong ambulant elderly population.
E.D. Janus*, M.C. Lee and S.S. Cheung.
172. Hyperlipidaemia, coronary heart disease prevention - implications from recent trials. Princess Margaret Hospital, Hong Kong, April, 1996.
E.D. Janus.
173. Hyperlipidaemia, coronary heart disease prevention - implications from recent trials. Hong Kong Adventist Hospital, May, 1996.
E.D. Janus (by invitation).
174. Third International Fibrinogen Symposium. Haemostasis, Inflammation and Cardiovascular Disease, Ulm, Germany, May, 1996.
Distribution of fibrinogen level and its relationship with age, body mass index, smoking and other risk factors of coronary heart disease in healthy Hong Kong Chinese.
E.D. Janus, L.T. Liu*, C. Bourke, T.H. Lam and A.J. Hedley.
175. 10th International Congress of Endocrinology, San Francisco, USA, June, 1996.
Acromegaly is associated with increased plasma cholesterylester transfer protein activity.
K.C.B. Tan*, S.W.M. Shiu and E.D. Janus.
176. 66th Congress of the European Atherosclerosis Society, Florence, Italy, July, 1996.
The modernization of Asia: Implications for coronary heart disease.
E.D. Janus*, R.B. Singh and A. Postiglione on behalf of the ISFC Council on Arteriosclerosis.
177. XVI International Congress of Clinical Chemistry, London, England, July, 1996.
Apparently low for CHD risk vitamin E concentrations in Chinese subjects in Hong Kong.
I.F.F. Benzie* and E.D. Janus.
178. Republic of China Society of Lipids and Atherosclerosis - Symposium on Hypertriglyceridaemia, Taipei, July, 1996.
Apolipoprotein(a) polymorphism in Hong Kong Chinese - Genetic and hormonal effects.
E.D. Janus (by invitation).
179. 3rd International Diabetes Federation Western Pacific Regional Congress, Hong Kong, September, 1996.
- (i) The prevalence of diabetes mellitus and impaired glucose tolerance in the Hong Kong population.
E.D. Janus*, C.S. Cockram, K.S.L. Lam and T.H. Lam for the Hong Kong Cardiovascular Risk Factor Prevalence Study Project Steering Committee.
 - (ii) Plasma apolipoprotein(a) levels and phenotypes in NIDDM patients with various stages of diabetic nephropathy.
R.W.C. Pang*, K.S.L. Lam, M.S. Wat, E.D. Janus.
180. Frontiers in Lipid and Lipoprotein Research, Dallas, Texas, USA, October, 1996.

A simplified SDS-agarose gel electrophoresis/immunoblotting method with chemiluminescent detection for apolipoprotein(a) phenotyping.

R.W.C. Pang*, E.D. Janus, K.S.L. Lam, A. Lingenhel and H.G. Kraft.

181. University of Hong Kong, Medical Faculty Research Day, Hong Kong, November, 1996. Apolipoprotein(a) polymorphism in Hong Kong Chinese: Genetic and hormonal effects. R.W.C. Pang*, E.D. Janus and K.S.L. Lam (Awarded best PhD poster prize).
182. Medical Research Conference '97, Department of Medicine, The University of Hong Kong, 25-26 January, 1997.
- (i) Apolipoprotein(a) polymorphism in Hong Kong Chinese: Genetic and hormonal effects. R.W.C. Pang*, E.D. Janus and K.S.L. Lam.
 - (ii) Delivery of Diabetes Care in Hong Kong. W.S. Chow*, E.D. Janus and K.S.L. Lam.
 - (iii) Genetic and environmental determinants of fibrinogen levels in Hong Kong Chinese: Studies in normal subjects and in diabetic patients. E.D. Janus, N.M.S. Wat*, O.C.K. Ma, C. Bourke and K.S.L. Lam.
 - (iv) Genetic influence on factor VII activity is overwhelmed by environmental factors in Chinese NIDDM patients. K.S.L. Lam*, E.D. Janus, O.C.K. Ma and C. Bourke.
183. 1st Hong Kong Medical Genetics Conference, Hong Kong, January, 1997. Disorders of Lipid Metabolism. E.D. Janus (by invitation).
184. Joint Meeting of the Philippine Lipid Society (3rd Annual Convention) and the Asian Pacific Society of Atherosclerosis and Vascular Diseases, Cebu, Philippines, March, 1997.
- (i) Atherosclerosis and Vascular Disease in Asia: An increasing health care concern. E.D. Janus.
 - (ii) Cardiovascular disease and cardiovascular risk factors. Recent epidemiologic data from China and Hong Kong. E.D. Janus for the Hong Kong Cardiovascular Risk Factor Prevalence Study Group.
 - (iii) A new dimension in the management of coronary heart disease. The 4S study and its implications. E.D. Janus.
185. Philippine Cardiac Rehabilitation Society Symposium. Manila, Philippines, March, 1997. A new dimension in the management of coronary heart disease. The 4S study and its implications. E.D. Janus (by invitation).
186. Fifth Annual Scientific Congress, Hong Kong College of Cardiology, Hong Kong, April, 1997.
- (i) Fibrinogen and other coronary heart disease risk factors in Hong Kong Chinese. The Hong Kong Cardiovascular Risk Factor Study. E.D. Janus, L.J. Liu*, C. Bourke and T.H. Lam for the Hong Kong Heart Health Steering Committee.

- (ii) Serum fatty acids in Chinese adults: Correlation with serum lipids and qualitative dietary data.
S.S.F. Leung*, X.H. Peng, Z.Y. Chen, S. Ho, J. Woo and E.D. Janus.
187. Inaugural Scientific Meeting of the Institute of Cardiovascular Medicine and Science. The University of Hong Kong, Hong Kong, April, 1997.
Epidemiology of Cardiovascular Risk Factors in Hong Kong.
E.D. Janus for the Hong Kong Cardiovascular Risk Factor Prevalence Study Group.
188. Association of Clinical Biochemists, National Meeting, Birmingham, England, May 1997.
Urate: A useful antioxidant or damaging prooxidant.
E.F.F. Benzie*, E.D. Janus and J.J. Strain.
189. Hong Kong Baptist Hospital Continuing Medical Education Scientific Meeting for Physicians, Hong Kong, May, 1997.
Lipids and lipoproteins - findings and implications from the Hong Kong Cardiovascular Risk Factor Prevalence Study.
E.D. Janus (by invitation).
190. 1997 Annual Scientific Meeting, New Zealand Atherosclerosis Society, Rotorua, New Zealand, June, 1997.
- (i) Cardiovascular risk factors and disease. A perspective from Asia.
E.D. Janus (by invitation).
- (ii) Apolipoprotein(a): Genetic and hormonal effects in expression.
E.D. Janus (by invitation).
191. 16th IDF Congress, Helsinki, Finland, July 1997.
Genetic and environmental determinants of factor VII activity in Hong Kong Chinese Diabetic patients.
K.S.L. Lam*, E.D. Janus, O.C.K. Ma and C. Bourke.
192. 1st Scientific Meeting of Thai Society of Atherosclerosis under the auspices of Asian-Pacific Society of Atherosclerosis, Phuket, Thailand, October, 1997.
Diabetes Mellitus and Atherosclerosis. E.D. Janus (by invitation).
193. Far East Lipid Forum, Penang, Malaysia, November, 1997.
Current perspectives on Primary Prevention - when to screen and whom to treat.
E.D. Janus (by invitation).
194. 1st Asia Pacific Congress on Hypertension, Surat, India, December 1997.
Austin Doyle Memorial Oration.
Blood Pressure in Hong Kong - Epidemiological Findings.
E.D. Janus (by invitation).
195. Hong Kong College of Cardiology. Symposium on Contemporary Management of Lipid Disorders, Hong Kong, January 1998.

An epidemiological study of risk factors in Hong Kong and South East Asia.
E.D. Janus (by invitation).
196. Australasian Association of Clinical Biochemists, Branch Meeting, Melbourne, February 1998

Diabetes, Hyperlipidaemia and Cardiovascular Disease - A Perspective from Asia.
E.D. Janus (by invitation).

197. First Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases, Taipei, March 1998.
Apolipoprotein(a) - A New Risk Factor - Genetic and Environmental Influences on Phenotypic Expression.
E.D. Janus (plenary lecture by invitation)
198. Australasian Association of Clinical Biochemists, Tasmanian Branch Meeting, Launceston, April 1998.
Diabetes, Hyperlipidaemia and Cardiovascular Disease - A perspective from Asia.
E.D. Janus (by invitation)
199. AACB/AIMS Victorian Branch - Combined State Scientific Meeting, Lorne, Victoria, May 1998.
Apolipoprotein(a) - A new risk factor - Genetic and Environmental Influences on Phenotypic Expression.
E.D. Janus (by invitation)
200. 3rd International Heart Health Conference, Singapore, August, 1998.
The Modernisation of Asia : Is an increase in Cardiovascular Disease the Inevitable Price?
E.D. Janus (by invitation)
201. A Practical Course in Epidemiological Methods conducted by NHMRC Clinical Trials Centre, University of Sydney, Australia; Clinical Trials and Epidemiology Research Unit, Singapore and Asian Pacific Society of Atherosclerosis and Vascular Diseases, Singapore, September 1998.

Design of Cross Sectional and Cohort Studies - The Hong Kong Cardiovascular Risk Factor Prevalence Study 1995 - 1996.
E.D. Janus
202. Victorian Heart Centre Course in Advanced Cardiology, Epworth Hospital, Melbourne, September 1998.
Update on lipids.
E.D. Janus (by invitation)
203. Victorian Heart Centre, CME Programme, Epworth Hospital, Melbourne, September, 1998.
The Hong Kong Cardiovascular Risk Factor Prevalence Study.
E.D. Janus (by invitation)
204. European Association for the Study of Diabetes. 34th Annual Meeting, Barcelona, Spain, September, 1998.
i) The β -cell glucokinase gene promoter G-A variant is associated with higher fasting glucose levels.
M. Zhang, N.M.S. Wat, S.S.M. Chung and K.S.L. Lam*
ii) Genetic and environmental determinants of plasminogen activator inhibitor-1 activity in Chinese diabetic patients.
K.S.L. Lam* N.M.S. Wat, B.S.H. Lam and E.D. Janus
205. Asian Clinical Trials Conference 1998, Hong Kong, October, 1998.
The modernization of Asia - implications for coronary heart disease.
E.D. Janus (by invitation)

206. Clinical Trials Centre, Faculty of Medicine, University of Hong Kong, Clinical Trials Research Methodology Course, Hong Kong, October, 1998.
Clinical trials study documents.
E.D. Janus (by invitation)
207. American Heart Association, 71st Scientific Sessions, Dallas, Texas, USA November, 1998.
Joint American Heart Association/Asian Pacific Society of Cardiology Symposium : Risk Factors and Prevention of Cardiovascular Disease.
Traditional Risk Factors and Changing Incidence of Cardiovascular Disease.
E.D. Janus (by invitation)
208. Perinatal Research Centre, Royal Women's Hospital, Melbourne, November, 1998.
Apolipoprotein(a) - Genetic and environmental influences on expression.
E.D. Janus (by invitation)
209. 12th Epworth Mountain Cardiology Seminar, Victorian Heart Centre, Dinner Plains, Victoria, Australia, November 1998.
- i) Lipid Management
E.D. Janus (by invitation)
 - ii) Epidemiology of Lipid Disorders in the Asian Pacific area.
E.D. Janus (by invitation)
210. University of Hong Kong Medical Alumni Association - Victorian Chapter Meeting, Melbourne, February, 1999
The Hong Kong Cardiovascular Risk Factor Study
E.D. Janus (by invitation)
211. Royal Children's Hospital Research Institute Seminar, Melbourne, March, 1999
The Hong Kong Cardiovascular Risk Factor Prevalence Study
E.D. Janus (by invitation).
212. Asian Pacific Society of Atherosclerosis and Vascular Diseases. Workshop "Genetic and Environmental Factors in Atherosclerosis, Osaka, Japan, April 1999
Cardiovascular Disease and Risk Factors in Asia
E.D. Janus (by invitation).
213. AIMS National workshops, Gold Coast, Queensland, May 1999
Atherosclerosis workshop
E.D. Janus (by invitation)
214. The 4th International Diabetes Federation Western Pacific Region Congress "Diabetes Towards 2000". Sydney, Australia, August, 1999.
Beta-fibrinogen gene G/A-455 polymorphism, fibrinogen levels and ischaemic heart disease in Hong Kong Chinese non insulin dependent diabetic patients.
E.D. Janus and K.S.L. Lam
215. 35th Annual Meeting of European Association for Study of Diabetes. Brussels, Belgium, September, 1999.
- (i) Evaluation of the 1997 ADA and 1998 WHO diagnostic criteria for diabetes in a chinese population.
K.S.L. Lam, N.M.S. Wat, T.H. Lam and E.D. Janus

(ii) The -258 G-A variant of the glucokinase gene hepatic promoter is associated with higher insulin sensitivity in Chinese.

M.Zhang, N.M.S.Wat, E.d.Janus, S.S.M. Chung and K.S.L Lam.

216. Australasian Association of Clinical Biochemists 37th Annual Scientific Conference , Melbourne, Australia, October, 1999.

Validation of smoking cessation: a novel HPLC urinary cotinine method.

R. Greaves and E.D. Janus.

Non insulin dependent diabetes mellitus in Hong kong – Studies of prevalence and of associated abnormalities of lipids, fibrinogen and factor VII.

E. D. Janus

217. International Congress on Atherosclerosis, Hypertension and Coronary artery Disease and 7th World Congress on Clinical Nutrition . New Delhi, India, 14 – 16 October, 1999.

Guidelines for prevention of Coronary Artery disease in Asia.

E.D.Janus

218. 13th Epworth Mountain Cardiology Seminar, Dinner Plain (via Mt Hotham), Victoria, Australia, 20 – 21 November, 1999.

The value of troponins in cardiac diagnosis.

E.D.Janus

219. Second Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases "Atherosclerosis by the year 2000" Chiang Mai, Thailand, Jan 30 - Feb 3, 2000.

Diabetes Mellitus and Atherosclerosis in the New Millenium (Plenary Lecture –Opening Session)

E.D.Janus (by invitation).

Glycaemic Control and Cardiovascular Involvement. In Symposium "Diabetes Mellitus and Cardiovascular Involvement".

E.D.Janus (by invitation).

220. Horsham and regional medical practitioners. Horsham 4th March, 2000.
Lipid lowering therapy.

E D Janus

221. Horsham and regional medical practitioners. Horsham, 7th April, 2000.
More effective antihypertensive therapy.

E.D.Janus

222. Horsham and regional medical practitioners. Horsham, 25th May, 2000.
The HOPE Study: Implications for patient care.

E.D.Janus.

223. 4th Annual Conference on Advances in Cardiology and Cardiovascular Therapeutics, The Heart Centre, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia, 21 –23 July, 2000. E D Janus (by invitation).
- (i) Optimising outcomes for the Diabetic with CAD
- (ii) Management of low low HDL
- (iii) Extending the Therapeutic Impact of Statins beyond LDL Control
224. XIIth International Symposium on Atherosclerosis, Stockholm, Sweden 25 – 29 June, 2000
- (i) Diabetes and obesity in CHD patients in the Asia-Pacific region: The ASPAC Study
C.E.Tan, G. Ritchie, K.Lin, E. Janus, D. Kusmana and A.Keech for the Asia Pacific CHD Risk Factor Collaborative Group; NHMRC Clinical Trials Centre, Sydney, Australia.
- (ii) Cholesterol ester transfer protein activity and hyperalphalipoproteinaemia in Chinese
K.C.B Tan, S.W.M. Shiu, E.D.Janus Department of Medicine, University of Hong Kong, Hong Kong, China and Melbourne Lipid Clinic, Melbourne ,Australia.
225. Atherosclerosis: Beyond Primary Prevention, Kuala Lumpur, Malaysia, January 11 –14, 2001.
Risk factors for Atherosclerosis in the Elderly
E. D. Janus (by invitation).
226. Joint 7th Annual Convention Conquering atherosclerosis: A Multi Specialty Approach, Philippine Society of Hypertension and Pilippine Lipid society, Manila, Philipinnes, February 5 – 7, 2001.
- (i) Oxidative Stress –A Therapeutic Target in Atherosclerosis
E.D.Janus (by invitation)
- (ii) What to do with Children and adolescents with Dyslipidaemia
E.D.Janus (by invitation).
227. Australian Atherosclerosis Society 27th Annual scientific meeting with Asian Pacific Society of Atherosclerosis and Vascular Diseases, Fremantle WA, Australia, 22 –25 November, 2001.
Cardiovascular Risk factors and Cardiovascular Disease Contrasts in Chinese Populations from Beijing, Hong Kong and Singapore.
ED Janus, S Emmanuel, Z Wu, C Zhang, KL Hynes and T Dwyer.
228. Heart Research Centre Training program in Cardiovascular Disease Rehabilitation and Prevention. Royal Melbourne Hospital, 26 – 30 November, 2001.
Cardiovascular Disease Risk Factors ED Janus (by invitation).
229. The Third Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases “Alliance Against Atherosclerosis” Cebu, Philippines, 17 –20 February,2002.
- (1) Challenges in the Prevention of Atherosclerosis in the Asian Pacific Region
E D Janus Opening Plenary Session by invitation- Delivered by AR Keech following deathof Mary Janus on 16/2/02.
- (2) Diabetes and cardiovascular Diseases. Prevalence of CVD in Diabetes.E D Janus (by invitation) delivered by C E Tan.

230. 2nd International Congress on Cardiovascular Diseases, Kosice, Slovakia, April 25 – 27, 2002. Challenges in the Prevention of Atherosclerosis in the Asian Pacific region.
E D Janus (by invitation).
231. XIVth World Congress of Cardiology, Sydney, Australia, 5-9 May, 2002.
Asian Diets.
E D Janus (by invitation).
232. International Cardiac Rehabilitation Scientific Meeting, Sydney, Australia, 9-11 May, 2002.
Asian Diets.
E D Janus (by invitation).
233. West Victorian Division of General Practice. Warrenmang, 1 June, 2002.
Update on Diabetes
E D Janus (by invitation)
234. SCOPE Presentation to General Practitioners and Resident Staff (Astra Zenica).
Horsham, 18 July, 2002
The Study of Cognition and Prognosis in the Elderly.
E D Janus
235. Heart Research Centre Training Programme in Cardiovascular Disease Rehabilitation and Prevention. Royal Melbourne Hospital, 22 July, 2002
Cardiovascular Risk Factors
ED Janus (by invitation).
236. General Practitioners Tutorial Group (BMS) Horsham, 23 July, 2002.
Integrated disease management for the secondary prevention of cerebrovascular events.
E D Janus
237. EASD Annual Meeting, Budapest, Hungary, 1-5 September, 2002.
Interaction between environmental factors and a common genetic variant of the glucokinase gene islet specific promoter on fasting glucose in a prospective study of nondiabetic Chinese.
KSL Lam, NMS Wat, M Zhang, AWK Tso, E D Janus, SSM Chung. (submitted).
238. Thai Atherosclerosis Society, 2nd Annual Scientific Meeting, 30-31 January, 2003, Bangkok, Thailand.
Pleiotropic effects of antidiabetic agents
E.D.Janus (by invitation).
239. Korean Society of Lipids and Atherosclerosis, Seoul., Korea, 7 – 8 March, 2003
Diabetes, Metabolic Syndrome and Cardiovascular Disease
E. D. Janus (by invitation).
240. Australian Council of Chinese Medical Associations -ACCMA –Annual Scientific, Conference, Canberra, 18-21 April, 2003.
Advances in Atherothrombosis Management Strategies.
E.D.Janus (by invitation).
241. Heart Research Centre Training Programme in Cardiovascular Disease Rehabilitation and Prevention. Royal Melbourne Hospital, 9th May, 2003.
Cardiovascular Risk Factors.
ED Janus (by invitation).

242. Rural health Week “Real Food for Real Communities”, Stawell, 4 June, 2003
Diet, Lifestyle and the Prevention of Diabetes and Coronary Heart Disease.
E D Janus (by invitation).
243. Heart Research Centre Workshop “Growing Healthy Country Hearts.”
Warrnambool, 18 –19 July, 2003.
Cardiovascular Risk Factors.
ED Janus (by invitation).
244. XIIIth International Symposium on Atherosclerosis. Sattellite Meeting, Taipei, Taiwan,
September 24 – 26, 2003
(i) The Role of Clopidogrel in Acute and Chronic Atherothrombosis Management
E D Janus - Symposium speaker by invitation.
(ii) Herbal Remedies in Cardiovascular Disease – increasing Use and Particular issues in western
countries
E D Janus - Plenary Lecture by invitation.
245. XIIIth International Symposium on Atherosclerosis. Kyoto, Japan,
September 28 – October 2, 2003.
Metabolic Syndrome and its Relevance to Asia
E D Janus Workshop Speaker and Co- Chairman by invitation.
246. XIIth International Symposium on Atherosclerosis satellite meeting and
5th Hong Kong Diabetes and Cardiovascular Risk Factors – East meets West Symposium, Hong
Kong, October 3 – 5, 2003.
Metabolic Syndrome in the Asian Pacific Region – Genotype or Phenotype
E D Janus (by invitation).
247. Grand Rounds, Ballarat Base Hospital, 31st October, 2003
Diabetes and Atherosclerosis The HPS Diabetes substudy
E D Janus (by invitation).
248. Bendigo Physicians Meeting, 31st October, 2003
Diabetes and Atherosclerosis The HPS Diabetes substudy, Metabolic Syndrome and Ezetimibe
therapy
E D Janus (by invitation).
249. West Victorian GP Education , Horsham 12th November 2003.
Tackling Cardiovascular disease in the 21st century. An update The EUROPA Study.
E D Janus
250. West Victoria GP Education , Horsham 3rd December, 2003.
Prandial Glucose regulation
E D Janus
251. 9th Medical Research Conference, Medical Science Group, The University of Hong Kong, 7-8
February, 2004.
The adiponectin T45G polymorphism is associated with central obesity and glucose intolerance in
southern Chinese.
AWK Tso, NMS Wat, A Xu, R Rong, KY Cheng, HY Fong, ED Janus and KSL Lam.
252. 4th Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases, Bali,

Indonesia, 6 – 9 May, 2004.

(i).Atherogenic dyslipidaemia as a coronary risk factor

E D Janus by invitation

(ii)Traditional Medicines in Atherosclerosis: Pros and contras

E D Janus by invitation.

253. VMPF Lecture. Wimmera Base Hospital, 29 July, 2004.
Management of Hypertension
E D Janus (by invitation).
254. 12th International Congress of Endocrinology, Lisbon, Portugal, 31 August 2004.
The adiponectin gene G276T polymorphism is a risk factor for the development of the metabolic syndrome over a period of 5 years in southern Chinese.
AWK Tso, NMS Wat, A Xu, PC Sham,R Rong,KY Cheng, HY Fong, ED Janus and KSL Lam.
255. 12th International Congress of Endocrinology, Lisbon, Portugal, 31 August 2004.
The adiponectin gene T45G polymorphism is associated with central obesity and persistent glucose intolerance in high risk Chinese subjects over 5 years.
NMS Wat, AWK Tso, A Xu, PC Sham,R Rong,KY Cheng, HY Fong, ED Janus and KSL Lam.
256. 6th APACPH Annual Conference, Public Health Networks and Alliances: Building capacity in the Asia – Pacific Region, Brisbane, Australia, 1 – 3 December 2004.
The Greater Green Triangle Diabetes Prevention Project
T Laatikainen, L Franklin, R Sager, E Janus, J Dunbar, P Absetz, A Nissinen, E Vartiainen, J Best, D Young, S Hunt.
257. Update in Cardiovascular disease and diabetes in the Greater Green Triangle - Pharmacists
Teleconference from Horsham 7th December 2004.
E D Janus
258. 10th Medical Research Conference, The University of Hong Kong, 19-20 February, 2005.
The G/G genotype of the -420 C>G polymorphism in the resistin gene promoter is associated with post-challenge glycaemia in southern Chinese.
J Xu, NMS Wat, A Xu, KY Cheng, PC Sham, ED Janus and KSL Lam.
259. VMPF Lecture. Wimmera Base Hospital, 3 March, 2005
Herbal Medicines and Cardiovascular Disease
ED Janus (by invitation).
260. West Victorian GP Education Horsham 7 April 2005
Evaluating and Managing Cardiovascular Risk - The Limestone Coast Example
E D Janus
261. West Victorian GP Education Horsham 28 April 2005
Heart Failure Management Case Study Teaching
E D Janus
262. The Endocrine Society's 87th Annual Meeting, San Diego, USA, 4-7 June, 2005.
The G/G genotype of the -420 C>G polymorphism in the resistin gene promoter is associated with post-challenge glycaemia in southern Chinese.
J Xu, NMS Wat, A Xu, KY Cheng, PC Sham, ED Janus and KSL Lam.

263. 2005 General Practice & Primary Health Care Research Conference, Adelaide, 26–28 July, 2 The Greater Green Triangle Diabetes Prevention Project.
A Chapman., J Dunbar, E Janus, T Laatikainen, S Heistaro, P Reddy.
264. American Heart Association Annual Scientific Meeting, Dallas, Texas, USA. November 2005
High density lipoprotein cholesterol and the metabolic syndrome in the Hong Kong
Cardiovascular Risk Factor Prevalence Study 1995 – 2004.
BMY Cheung, NMS Wat, YB Man, KSL Lam, TH Lam, SCF Tam, GM Leung, CH Cheng, CR
Kumana, CP Lau, ED Janus (submitted).
265. Cardiovascular Disease, Diabetes and Heart Failure Update for Wimmera Pharmacists, Horsham,
VIC. 5th July 2005.
ED Janus (by invitation).
266. Mallee Division of General Practice
Preventing Heart Disease and Diabetes
Hopetoun, 19th July, 2005.
ED Janus (by invitation).
267. Cardiac Society of Australia and New Zealand Annual Scientific Meeting, Perth 5-8 August 2005.
Limestone Coast Risk Factor Study.
P Tideman, T Laatikainen, JA Dunbar, ED Janus, R Tirimacco
268. Ballarat General Practitioners Seminar, Ballarat, 5th October, 2005.
Recent Advances in Lipid Management
ED Janus (by invitation).
269. Grand Round Western Hospital, Footscray, Victoria, 7th October, 2005.
Cardiovascular Risk Factors and Diabetes – Epidemiology and Prevention.
ED Janus (by invitation).
270. Australasian Society for the Study of Obesity, 14th Annual scientific Meeting, Adelaide, Australia,
October 28-30, 2005.
Overweight and Obesity in Australia
S Heistaro, E Janus, P Tideman, A Baird, T Laatikainen and J Dunbar on behalf of the Greater
Health Cardiovascular Risk Factor Study Group.
271. 5th Congress of the Asian Pacific Society of Atherosclerosis and Vascular diseases, Jeju, Korea
April 12 -15, 2006.
Nuclear receptors. Targets for new therapeutic interventions in atherosclerosis.
E D Janus (by invitation).
272. The Endocrine Society's 88th Annual Meeting, Boston, USA, 24-27 June, 2006.
Adiponectin is predictive of changes in diastolic blood pressure over 5 years in Chinese women.
WS Chow, AWK Tso, LHY Ong, NMS Wat, A Xu, CHY Fong, ED Janus, KSL Lam.
273. 2006 General Practice and Primary Health Care Research Conference: Optimising Impact. Perth,
Australia, 5-7 July, 2006.
A population based approach to optimising antihypertensive use.
K McNamara, S Heistaro, A Kilkkinen, E Janus, P Tideman, A Baird, T Laatikainen, J Dunbar.
274. Australian Diabetes Society & Australian Diabetes Education Association Annual Scientific

Meeting, Broadbeach, QLD 23-25 August 2006
 The Greater Green Triangle Diabetes Prevention Project.
 A Chapman, JA Dunbar, S Bunker, ED Janus, A Kilkinen, S Heistaro, T Laatikainen.

275. Horsham and Regional General Practitioners, Horsham, 5th September 2006.
 Metabolic syndrome.
 E D Janus (by invitation).
276. Developmental Origins of Health and Disease (DOHAD) Conference, Utrecht, The Netherlands, September 2006.
 Explaining the diabetes epidemic in Chinese – preliminary evidence from Hong Kong as a natural experiment in epidemiological time.
 M Schooling, TH Lam, ED Janus, BJ Cowling, G Leung for the Hong Kong Cardiovascular Risk Factor Prevalence Study Steering Committee
277. Wodonga and Regional General Practitioners, Wodonga, 11th October, 2006.
 Metabolic syndrome & diabetes Management.
 E D Janus (by invitation).
278. 3rd Asian Pacific Congress on Heart Failure, Taipei, Taiwan, 27-30 October, 2006.
 How to design Programs of Care to Prevent Readmission.
 E D Janus (by invitation).
279. 10th Anniversary Scientific Meeting, The Institute of Cardiovascular Science and Medicine, Faculty of Medicine, The University of Hong Kong, Hong Kong, 9-10 December, 2006.
 Overweight, Obesity and Metabolic syndrome – An Asian Pacific Perspective.
 E D Janus (by invitation).
280. 1st Joint Meeting between APSAVD and 5th Annual Scientific Meeting of the Thai Atherosclerosis Society “Stem Cell Therapy in Atherosclerosis”
 New Paradigm in disease management – Lifetime risk management
 E D Janus (by invitation).
 Regression of Atherosclerosis – Fact or Fancy
 E D Janus (by invitation)
281. Horsham and Regional General Practitioners, Horsham, 12 June 2007.
 Management of Hypertension
 E D Janus (by invitation).
282. Williamstown General Practitioners, 16 August 2007.
 GGT hypertension results and Management of Hypertension
 E D Janus (by invitation).
283. Servier Laboratories Annual Country Physicians Meeting
 Melbourne 18 August, 2007
 Key Findings from the Greater Green Triangle Risk Factor Survey
 E D Janus (by invitation).
284. Ballarat General Practitioners, 22 August 2007.
 GGT hypertension results and Practical Approaches to Achieving and Sustaining BP Goals.
 E D Janus (by invitation).

285. 9th Hong Kong Diabetes and Cardiovascular Risk Factors - East meets West Symposium
Hong Kong 30 September - 1 October 2007
Treatment Gaps in Hypertension and Hypercholesterolaemia
E D Janus (by invitation).
286. Blood and Bones Seminar for General Practitioners, Queenscliff, 27 October, 2007
Treatment gaps in hypertension. Intensifying hypertension management.
E D Janus (by invitation).
287. Sixth Rural Weekend Update on Cardiovascular Management. Integrated Clinical Cardiovascular
Network South Australia (iCCnet SA).
Metabolic Syndrome and Cholesterol Management.
E D Janus (by invitation).
288. Cobram area General Practitioners, 13 November 2007.
Risk matters 2. Hypertension management in high risk patients.
E D Janus (by invitation).
289. Mildura area General Practitioners, 28 November, 2007
Risk matters 2. Finding atherosclerosis - strategies to identify the at-risk patient.
E D Janus (by invitation).
290. The 2nd Joint Meeting between APSAVD and The 6th Annual Scientific Meeting of Thai
Atherosclerosis Society "New Horizon and Novel Therapy".
Kanchanaburi, Thailand, 26 - 27 January, 2008.
- Clopidogrel: Past, present and Future Directions.
E D Janus (by invitation).
- Detection and Treatment of Insulin Resistance
E D Janus (by invitation).
291. Cardiac Society of Australia and New Zealand, 56th Annual Scientific Meeting,
Adelaide 7th -10th August, 2008.
- Management of Lipids in Rural Australia-Are the Guidelines Being Followed?
Philip Tideman, Rosy Tirimacco, Edward Janus, Benjamin Philpot, Stephen Bunker, Kevin
McNamara, Tiina Laatikainen, Annamari Kilkinen, Sami Heistaro, James Dunbar.
- Detection and Treatment of Hypertension in Rural Australia (poster presentation)
Philip Tideman, Rosy Tirimacco, Edward Janus, Stephen Bunker, Annamari Kilkinen, Kevin
McNamara, Benjamin Philpot, Tiina Laatikainen, Sami Heistaro, James Dunbar.
292. 6th Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases & 10th Hong
Kong Diabetes and Cardiovascular Risk Factors East Meets West Symposium, Hong Kong 25-28
September 2008.
- Case Finding and Diabetes Prevention - A National Programme
E D Janus (by invitation).
293. Australian Atherosclerosis Society Annual Scientific Meeting, Sydney October 28-31, 2008

Are the Guidelines Being Followed?

Edward Janus, Philip Tideman, Rosy Tirimacco, Benjamin Philpot, Stephen Bunker, Kevin McNamara, Tiina Laatikainen, Annamari Kilkinnen, Sami Heistaro, James Dunbar.

294. 3rd International congress on Prediabetes and the Metabolic Syndrome, Nice France, April 1-4, 2009.
- Association between raised Blood Pressure and Dysglycaemia in Hong Kong Chinese.
BMY Cheung, NMS Wat, AWK Tso, S Tam, GN Thomas, GM Leung, HF Tse, J Woo, ED Janus, CP Lau, TH Lam, KSL Lam.
295. European Diabetes Epidemiology Group 44th Annual Meeting, Wageningen, Netherlands, May 9-12, 2009.
- Blood lipid levels in relation to glucose status in 7 populations of Asian origin without a prior history of diabetes: The DECODA Study.
L Zhang, Q Qiao, J Toumilehto, N Hammar, E D Janus, S Soderberg, V Mohan, A Ramachandran, Y Dong, TH Lam, Z Pang for the DECODA Group.
296. Stawell area General Practitioners, 11 June, 2009.
Treatment priorities in type 2 diabetes management
E D Janus (by invitation).
297. Women's Wellness West Network Seminar. Understanding Diabetes: Facts and Management in a Diverse Population, Melbourne, 25 June, 2009.
- Diabetes - The new world epidemic - What it means for you and me.
E D Janus (by invitation).
298. 2009 General Practice and Primary Health Care Research Conference, Melbourne, Australia, 15-17 July, 2009.
- Does the dose of telephone support intervention influence health outcomes?
N Davis-Lameloise, C Vaughan, B Philpot, E D Janus, P Reddy, JA Dunbar.
- Addressing evidence treatment gaps for cardiovascular disease through primary care collaboration.
K McNamara, E D Janus, B Philpot, T Laatikainen, J A Dunbar.
299. 69th International Congress of Federation Internationale Pharmaceuticale, Istanbul, Turkey, September 2009.
- Primary prevention of cardiovascular disease in community pharmacy: developing a framework for implementation.
K McNamara, J George, S Jackson, G Peterson, H Howarth, JA Dunbar, E Janus, J Finch, S Bunker, L Morabito, P Trinder, S O'Reilly, G Duncan, J Emery (Oral).
- Clinical outcomes from a community pharmacy feasibility study for the primary prevention of cardiovascular disease.
K McNamara, G Peterson, J George, S Jackson, H Howarth, S O'Reilly, JA Dunbar, P Trinder, J Finch, S Bunker, E Janus, L Morabito, J Emery, G Duncan (Poster).

Identifying specific cardiovascular health opportunities for community pharmacy: a population health approach.

K McNamara, E Janus, B Philpot, T Laatikainen, J Dunbar (Poster).

300. IDF 20th World Diabetes Congress, Montreal, Canada, 18-22 October, 2009.

Sustained gains from a primary care based Diabetes Prevention Program

J A Dunbar, N Davis-Lameloise, B Philpot, P Reddy, AS Chapman, S Heistaro, E D Janus (oral presentation).

Weight misperceptions in rural Australia: recognising weight status in an environment where overweight and obesity are the norm.

R Boak, B Philpot, JA Dunbar, A Hernan, N Davis- Lameloise, E D Janus (poster presentation).

301. Asia Pacific Conference on the Metabolic Syndrome, Melbourne, Australia, 20-21 November, 2009.

Preventing Diabetes and the Metabolic Syndrome - The Greater Green Triangle Diabetes Prevention Project.

E D Janus (by invitation).

302. 3rd Joint Meeting between APSAVD and 8th Annual Scientific Meeting of the Thai Atherosclerosis Society, Cha-AM , Thailand, 23-24 January, 2010.

Diabetes Mellitus:Comprehensive Management of Cardiovascular Risk.

E D Janus (by invitation).

Obesity, Sleep Apnea and Cardiovascular risks.

E D Janus (by invitation).

303. Pharmacy Practice Research Summit, Canberra, Australia, 2-4 March, 2010.

Community pharmacists preventing primary onset of cardiovascular disease: key clinical outcomes.

K McNamara, G Petersen, J George, S Jackson, H Howarth, S O'Reilly, JA Dunbar, P Trinder, J Finch, S Bunker, E Janus, L Morabito, J Emery, G Duncan, M Bailey (Invited poster).

Community pharmacists preventing primary onset of cardiovascular disease: developing a model of care.

K McNamara, J George, S Jackson, G Petersen, H Howarth, JA Dunbar, E Janus, J Finch, S Bunker,L Morabito, P Trinder, S O'Reilly, G Duncan, J Emery (Invited poster).

304. Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions, San Francisco, USA, April 8-10, 2010.

Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects.

EMM Ooi, ED Janus, S J Grant, L M T Sinclair, P H R Barrett (poster).

305. European Conference on Health Economics, Helsinki Finland, 7-10 July 2010.

Economic evaluation of the Melbourne diabetes prevention study: an intervention for individuals 50 or older at high risk of developing Type 2 diabetes.
B Murphy, S Colgan, R Carter, E Janus, P Reddy, E Vartiainen, J Dunbar (oral).

306. Inaugural National Centre for Farmer Health Conference, Hamilton, VIC, Australia, 11-13 October, 2010.

Chronic Disease Risk Factors in Rural Areas: The Greater Green Triangle Risk Factor Study.
B Philpot, N Lameloise-Davis, ED Janus, T Laatikainen, JA Dunbar.

307. General Medicine Clinical Weekend: Clinical Internal Medicine for Advanced Trainees and Consultants, Torquay, VIC, Australia, 15-16 October, 2010.

Puzzling Abdominal Pain - A Review of Porphyrias.

E D Janus by invitation.

308. Joint 7th APSAVD Congress and AAS Annual Scientific Meeting, Cairns Australia, October 26-29, 2010.

Distinct differences in blood pressure levels across glucose categories

L Zhang, Q Qiao, ED Janus#, TH Lam, CDA Stehouwer, S Soderberg V Mohan, J Tuomilehto, for the DECODE/DECODA Group.

Distinct differences in lipid levels across glucose categories

L Zhang, Q Qiao, J Tuomilehto, ED Janus#, TH Lam, A Ramachandran, A Nakagami, S Soderberg for the DECODE/DECODA Group.

GRANTS AWARDEDNational Heart Foundation of New Zealand

In New Zealand the NHF is the main funding body for cardiovascular research

No. 150 E.D.Janus 1977 (1 year) NZ\$15,000
Overseas research fellowship

No. 233 E.D.Janus 1980 - 83 (3 years) NZ\$48,000

No. 356 E.D.Janus 1983 - 85 (2 years) NZ\$44,000

Project grants terminating December 1984 on my departure

No. 270 R.W.Carrell and E.D.Janus
1981 - 84 (3 years) NZ\$20,000

No. 393 R.W.Carrell and E.D.Janus
1984 - 86 (2 years) NZ\$25,000

Project grants terminating March 1986 on completion of Ph.D. student project.

New Zealand Government Lead Research Grant

E.D.Janus and D.Hinton 1984 - 87

Grant continued after my departure. NZ\$120,000

MRC (N.Z.)

R.W. Carrell, E.D.Janus and C.Winterbourn

Programme Grant 1981 - 84 NZ\$250,000

National Heart Foundation of Australia

E.D.Janus and J.D.Best, 1986 - 88 (3 years).

Project grant. A\$75,000

Merck, Sharp and Dohme Fellowship in Lipid Metabolism

Dr A.Jenkins to work with Dr E.D.Janus 1989-91(2 years) A\$60,000

Commonwealth Serum Laboratories

Drs E.D.Janus and J.Burdon. 1989 - 91 (2 years) A\$170,000

Alpha-1-antitrypsin replacement therapy

1991 - 92 (renewal) A\$105,000

1992 - 93 (renewal) A\$125,000

Jack Brockhoff Foundation

Antiproteases in lung disease

A\$50,000

J.G.W. Burdon, E.D. Janus & K.R. Knight. 1993 - 94

HKU Committee on Research and Conference Grants

Genetic and environmental influences on apolipoprotein(a)
in insulin dependent diabetes mellitus

HK\$92,500

E.D. Janus, K.S.L. Lam and S.C.F. Tam. 1993 - 94

Merck, Sharp & Dohme (Asia) Ltd.

Simvastatin and gemfibrozil in Renal transplantation

| | |
|--|-------------|
| I.K.P. Cheng & E.D. Janus. 1993 - 94 | HK\$146,000 |
| <u>HKU Committee on Research and Conference Grants</u> Hormonal and genetic interactions in apolipoprotein(a) phenotypic expression E.D. Janus, Y.F. Chan, A.W.C. Kung and K.S.L. Lam. 1994 - 95 | HK\$116,400 |
| <u>Research Grants Council, Hong Kong</u> Genetic and hormonal interactions in apolipoprotein(a) phenotypic expression E.D. Janus, K.S.L. Lam and A.W.C. Kung. 1994 - 96 | HK\$503,000 |
| <u>Lee Wing Tat Medical Research Fund</u> Hormonal and genetic interactions in apolipoprotein(a) phenotypic expression E.D. Janus. 1994 - 95 | HK\$25,000 |
| <u>Hong Kong Society for the Aged</u> Geriatric reference ranges E.D. Janus. 1994 - 95 | HK\$200,000 |
| Hong Kong Cardiovascular Risk Factor Prevalence (Pilot Study) E.D. Janus. 1993 - 94 | HK\$80,000 |
| <u>Hong Kong Health Services Research Committee</u> Hong Kong Cardiovascular Risk Factor Prevalence Study (Phase I). E.D. Janus. 1994 - 96 | HK\$500,000 |
| <u>Hong Kong Health Services Research Committee</u> Hong Kong Cardiovascular Risk Factor Prevalence Study - Dietary survey (with J. Woo, CUHK) 1995 - 96 | HK\$500,000 |
| <u>Hong Kong Health Services Research Committee</u> Hong Kong Cardiovascular Risk Factor Prevalence Study - Case Control Study (with T.H. Lam and Dr. C.P. Lau). 1995 - 96 | HK\$668,000 |
| <u>HKU Committee on Research and Conference Grants</u> Hyperinsulinaemia and cardiovascular risk factors in Hong Kong Chinese E.D. Janus and K.S.L. Lam. 1995 - 96 | HK\$76,000 |
| <u>HKU Committee on Research and Conference Grants</u> Prothrombotic and fibrinolytic factors in diabetic nephropathy K.S.L. Lam, E.D. Janus and L.C. Chan. 1995 - 96 | HK\$136,000 |

| | |
|---|---------------|
| <u>Sandoz Pharmaceuticals Ltd. (Hong Kong)</u> The efficacy and safety of fluvastatin in CAPD patients with hypercholesterolaemia C.S. Li, S.C. Tiu and E.D. Janus. 1994 - 97 | HK\$200,000 |
| <u>Research Grants Council, Hong Kong</u> Metabolic disturbances after traumatic brain injury - a study by microdialysis K.H. Chan, E.D. Janus, Y.M. Chan and C.F. Fung. 1995 - 97 | HK\$1,178,000 |
| <u>Hong Kong Health Services Research Committee</u> Cyclosporine dosage & cotreatment with diltiazem in renal transplant patients C.R. Kumana, D.T.M. Chan, C.S. Li, M.K.L. Tang, I.J. Lauder and E.D. Janus. 1997 - 98 | HK\$730,000 |
| <u>Hong Kong Health Services Research Committee</u> (HSRC 711027) Impaired glucose tolerance as a precursor of Diabetes and Hypertension in Hong Kong Chinese K.S.L. Lam, N.M.S. Wat, E.D. Janus and T.H. Lam 1997 - 1999 | HK\$316,336 |
| <u>Research Grants Council, Hong Kong</u> (HKU 7290 (97 M)) Clinical, biochemical and genetic factors predicting the development of diabetes mellitus and hypertension in Hong Kong Chinese with impaired glucose tolerance (IGT) K.S.L. Lam, E.D. Janus and N.M.S. Wat 1997 - 1999 | HK\$345,600 |
| <u>Research Grants Council, Hong Kong</u> Interactions between smoking, diabetes mellitus and genes affecting lipoprotein coronary heart disease risk factors J.R.L. Masarei, E.D. Janus and C.P. Pang 1997 – 1998 | HK\$349,000 |
| <u>Department of Human Services Victoria</u> Improving anticoagulation Management in a rural and remote population. A.Wolff, E Janus, R Grenfell, D Norton, S Taylor & J Measday 2002-2005 | A\$363,683 |
| Australian Government Department of Health and Aging The Greater Green Triangle Diabetes Prevention Project J Dunbar et al. 2004-2005. including E D Janus (lead clinician for GGT DPP) | A\$198,980 |
| sanofi-aventis Australia pty limited. Venous Thromboembolism Taskforce Audit E D Janus 2007-2008. | A\$49,500 |

| | |
|---|--------------|
| sanofi-aventis Australia pty limited. Venous thromboembolism prevention & Detection and management of osteoporosis E D Janus and P R Ebeling (2008). | A\$50,000 |
| NHMRC Project Grant Life! vs usual care in diabetes prevention: a critical evaluation. JA Dunbar, RC Carter, ED Janus, SK Lo, P Reddy, E Vartianen (2009-2011). | A\$833,125 |
| sanofi-aventis Australia pty limited. Electronic VTE risk assessment elVis E D Janus (2009-2010). | A\$120,000 |
| MHMRC Partnership Grant Preventing diabetes in Pregnancy from Progressing to Type 2 Diabetes: Macro-level system change in South Australia and Victoria JA Dunbar, JD Best, ED Janus, R Carter, J Oats, P Reddy, J Carnie and P Phillips. (2010-2014). | A\$1,292,000 |